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Advanced radiation therapy techniques rely on a modulation of the fluence fields to opti-
mize the clinical benefit of the treatment. This increased flexibility for intensity-modulated
radiation therapy (IMRT) in comparison to conventional techniques allows the realization
of excellent dose distributions. However, the advantage of superior dose distributions for
IMRT usually requires an increased treatment time. A dose delivery technique with the
potential to overcome this problem without impairing the treatment quality is dynamic
rotation therapy in a single arc. This technique uses dynamic field shaping with a multi-
leaf collimator (MLC) and a variable dose rate of the linac during irradiation to conform
the dose distribution to the target volume. This thesis introduces an optimization concept
for dynamic rotation therapy with variable dose rate, called arc-modulated cone beam
therapy (AMCBT), that also accounts for all practical limitations of this approach im-
posed by the dose delivery hardware. This optimization algorithm is applied to assess
the clinical potential of AMCBT via comparative treatment planning studies. Finally, a
first realization of AMCBT based on a Siemens ArtisteTM linac equipped with a dynamic
MLC was developed and investigated.
Optimierung, Realisierung und Qualita¨tsanalyse
der Kegelstrahl-Rotationstherapie
Moderne Techniken in der Strahlentherapie verwenden eine Modulation der Fluenzfelder
um den klinischen Nutzen einer Behandlung zu optimieren. Diese erho¨hte Flexibilita¨t
fu¨r intensita¨tsmodulierte Strahlentherapie (IMRT) im Vergleich zu konventionellen Tech-
niken ermo¨glicht die Realisierung von exzellenten Dosisverteilungen. Allerdings fu¨hrt
der Vorteil der verbesserten Dosisverteilung u¨blicherweise zu einer verla¨ngerten Behand-
lungszeit. Eine Bestrahlungstechnik mit dem Potenzial dieses Problem zu u¨berwinden
ohne die Qualita¨t der Behandlung zu beeintra¨chtigen ist die dynamische Rotationsthera-
pie in einer einzelnen Gantryumdrehung. Diese Technik verwendet eine dynamische An-
passung des Bestrahlungsfeldes mittels eines Multi-Lamellen Kollimators (MLC) und eine
variable Dosisrate des Beschleunigers wa¨hrend der Bestrahlung um die Dosisverteilung an
das Targetvolumen anzupassen. In dieser Doktorarbeit wird ein Optimierungskonzept fu¨r
die dynamische Rotationstherapie mit variabler Dosisrate, genannt Kegelstrahl-Rotations-
therapie (AMCBT), vorgestellt, welches auch alle praktischen Einschra¨nkungen durch
die Bestrahlungs-Hardware beru¨cksichtigt. Diese Optimierungsstrategie wurde verwen-
det um das klinische Potenzial von AMCBT in vergleichenden Planungsstudien zu un-
tersuchen. Schließlich wurde eine erste Realisierung von AMCBT basierend auf einem
Siemens ArtisteTM Beschleuniger mit dynamischen MLC entwickelt.
Contents
1 Introduction 1
2 Basics of Radiotherapy 5
2.1 Course of radiotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 Treatment delivery techniques . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.1 Fixed-field intensity-modulated radiation therapy . . . . . . . . . . . 8
2.2.2 Dynamic rotational treatment techniques . . . . . . . . . . . . . . . 8
2.3 Inverse treatment planning and dose optimization . . . . . . . . . . . . . . . 10
2.3.1 Principle of inverse planning for IMRT . . . . . . . . . . . . . . . . . 10
2.3.2 Optimization concepts for arc therapy with variable dose rate . . . . 12
2.4 Challenges in high precision radiotherapy . . . . . . . . . . . . . . . . . . . 14
3 Optimization concept for arc-modulated cone beam therapy 15
3.1 The optimization concept . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.1.1 Automated generation of initial field shapes . . . . . . . . . . . . . . 16
3.1.2 Optimization loop . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.2 Hardware limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
4 Treatment plan comparisons 27
4.1 Comparison of IMRT and AMCBT . . . . . . . . . . . . . . . . . . . . . . . 28
4.1.1 Prostate carcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.1.2 Paraspinal tumor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
4.1.3 Head tumor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
4.2 Comparison of tomotherapy and AMCBT . . . . . . . . . . . . . . . . . . . 33
4.2.1 Patient selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4.2.2 Treatment planning . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.3 Comparison of AMCBT and ”idealized IMRT” . . . . . . . . . . . . . . . . 43
5 Stability of AMCBT treatment plan quality 47
5.1 Hardware limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
5.2 Beam flattening filter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
5.3 Variation of optimization and delivery parameters . . . . . . . . . . . . . . 56
5.3.1 Number of beam directions . . . . . . . . . . . . . . . . . . . . . . . 59
5.3.2 Collimator angle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5.3.3 MLC leaf width . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
5.3.4 Constant dose rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5.4 Sensitivity of rotational therapy to dose delivery errors . . . . . . . . . . . . 65
vii
viii Contents
5.4.1 MLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
5.4.2 Dose rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
5.4.3 Gantry position . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
6 Hardware solution for AMCBT 73
6.1 Dose rate modulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
6.1.1 Dose rate modulation board . . . . . . . . . . . . . . . . . . . . . . . 73
6.1.2 Experimental verification of dose rate modulation . . . . . . . . . . 74
6.2 MLC control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
6.3 Gantry Rotation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
6.4 Dosimetric verification of AMCBT delivery . . . . . . . . . . . . . . . . . . 85
6.4.1 Methods and materials . . . . . . . . . . . . . . . . . . . . . . . . . . 85
6.4.2 Results 1: multi-ionization chambers . . . . . . . . . . . . . . . . . . 86
6.4.3 Results 2: film measurement . . . . . . . . . . . . . . . . . . . . . . 90
6.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
7 Discussion and conclusions 95
Bibliography 101
List of Figures 107
List of Tables 109
1 Introduction
Radiotherapy is a widely used approach for the treatment of cancer patients. In Germany,
the number of patients diagnosed with cancer is almost half a million every year [2]. Be-
sides cardiovascular diseases cancer is the most common cause of death. Radiation therapy
is employed to treat malignant tumors either as the primary therapy or in combination
with other treatment modalities such as surgery or chemotherapy. Whether the intent
of the treatment is curative or palliative depends on many factors, e.g. the tumor type,
the tumor stage or the tumor location. Ionizing radiation damages the DNA of the cells,
which might lead to cell death. The aim of a curative radiation therapy treatment is to
destroy all cancerous cells. The delivery of a lethal dose to the target volume will always
result in an irradiation of healthy tissue and organs at risk (OAR) in close proximity to
the tumor. The objective for planning a radiation therapy treatment is the optimization
of treatment parameters to achieve a high and homogenous dose in the tumor and to spare
the surrounding tissues and OARs as much as possible from dose.
Developments in treatment planning and dose delivery techniques resulted in methods
that allow dose shaping to highly complex geometries. In particular the introduction of
intensity modulated radiotherapy (IMRT) significantly increased the number of degrees
of freedom (DOFs) available for the dose delivery process. In standard cone beam IMRT
techniques a few beam directions are selected for which the modulation of the fluence
fields is optimized in the treatment planning process. Before starting the mathematical
optimization initial field shapes are determined by a projection of the radiation target on
to the isocentric plane perpendicular to the beam. Next, this field shape is subdivided
into numerous fluence bixels. The relative fluence weights of those bixels are optimized by
inverse planning. Finally, the optimized fluence profiles are converted into leaf-sequences
for dose delivery with a multi-leaf collimator (MLC) - a procedure that often deteriorates
the plan quality and leads to an unnecessary high number of beam segments.
To avoid this final step in the planning process which impairs the optimized dose distribu-
tion the method of direct aperture optimization (DAO) was developed [50]. In DAO the
shape of individual beam segments and their corresponding fluence weights are determined
simultaneously. This leads to the same plan quality with less segments and less monitor
units (MU) compared to the standard two-step planning approach [51]. A reduction of the
number of MUs needed for a specific treatment is beneficial since this reduces the scat-
tered and leakage radiation that is unintentionally delivered to a patient. A consequence
of an increased number of MUs is a higher risk to induce secondary malignancies with
radiotherapy [21].
Besides fixed field IMRT techniques also rotational dose delivery techniques were devel-
oped and used to treat cancer patients. A rotational dose delivery technique which delivers
highly conformal dose distributions is helical tomotherapy [29]. In helical tomotherapy the
patient is moved through the gantry bore while the treatment is performed with rotating
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fan beams, resulting in a helical dose delivery curve. The treatment machine for this tech-
nique is equipped with a fast pneumatically driven binary MLC to modulate the radiation
during dose delivery.
Another rotational intensity-modulated irradiation technique performed with a conven-
tional linear accelerator (linac) is intensity modulated arc therapy (IMAT) [75]. The
required fluence modulation is achieved by superimposing the dose from several arcs of
the rotating gantry with different weighting factors. A disadvantage of this technique is
the long treatment time which is needed for the delivery of several arcs.
A dose delivery within a single rotation of the gantry would decrease the treatment time
in comparison to other intensity-modulated radiotherapy techniques. To increase the flex-
ibility in treatment planning the additional DOF to vary the dose rate during irradiation
is introduced. This thesis project deals with a dose delivery technique which employs
variable dose rate and variable field shapes during irradiation: arc-modulated cone beam
therapy (AMCBT).
The objectives for the PhD thesis were
• the development of the optimization algorithm for arc-modulated cone beam therapy
• the assessment of achievable plan quality based on the developed optimization algo-
rithm
• the development of a hardware solution for the delivery of dynamic arc therapy with
variable dose rate.
The first publication of an optimization method for an intensity modulated treatment
technique that is restricted to a single arc with the possibility to vary the dose rate was
published in 2005 [10], called sweeping-window arc therapy (SWAT). The optimization al-
gorithm for AMCBT was published in 2007 [61]. At that time there was no dose delivery
hardware for dynamic arc therapy with variable dose rate available.
Based on the optimization algorithm described in [40] Varian developed a product for
single arc therapy called RapidArcTM . This delivery method was introduced in some ref-
erence clinics in 2008 and by now there is a huge increase in the number of centers using
RapidArcTM . Elekta also offers a dynamic arc product called VMATTM . The last year
showed a rapid increase in publications dealing with dynamic arc techniques. In chapter
2.3.2 several of the different optimization algorithms are introduced, a summary of the
results from different treatment plan comparisons is given in chapter 4.
This thesis is structured as follows: it starts with a short introduction of the basics of ra-
diotherapy, the focus of chapter 2 is on treatment planning and dose delivery techniques.
The optimization algorithm that was developed and tested during this work is described
in detail in chapter 3. The next two chapters show results obtained with this direct aper-
ture optimization algorithm. First, the dose distribution quality that is achievable with
AMCBT is assessed in comparison to fixed field IMRT and helical tomotherapy. These
studies show advantages and disadvantages of the new single arc dose delivery technique
with variable dose rate in comparison to state-of-the-art dose delivery techniques. Chap-
ter 4 closes those investigations with a comparison of AMCBT with an idealized form of
IMRT. In chapter 5 the stability of the treatment plan quality was analysed for several
hardware and optimization related aspects. In particular the influence of the following
3factors on the final dose distribution were considered: hardware limitations, primary flu-
ence, number of beam directions, employed collimator angle, MLC leaf width, variable vs.
constant dose rate. Moreover, the sensitivity of rotational therapy to dose delivery errors
was examined.
Besides the work on treatment planning a part of this thesis project is concerned with the
realization of a dose delivery hardware for dynamic arc therapy with variable dose rate.
The hardware solution for AMCBT that was implemented at the DKFZ is described in
chapter 6. First measurements have shown the feasibility to perform dynamic rotation
therapy with variable dose rate with a Siemens ArtisteTM linac.
Parts of this work have been previously presented at international conferences [60], [62],
[63], [65] and were published in peer-reviewed journals [61], [64].
2 Basics of Radiotherapy
The aim of radiotherapy is the delivery of a lethal dose to the tumor while sparing the
surrounding healthy tissue from dose as much as possible. In this chapter the steps of the
radiation therapy treatment process are introduced, with a focus on the components that
are most relevant for this thesis: treatment planning and dose delivery.
In radiation therapy, cancerous cells are killed by the deposition of dose by ionizing ra-
diation. Energy dose is defined as the energy that is absorbed by the irradiated mass
(D = dE
dm
). Naturally, the deposition of dose does not only kill cancerous cells but also
healthy cells. To avoid severe side effects caused by irradiation it is important to spare
the surrounding tissue and radiation sensitive organs at risk (OARs) from dose as much
as possible. To achieve this goal dose delivery techniques were developed that utilize a
high number of degrees of freedom to shape the dose to the target volume.
Radiotherapy utilizes different types of radiation, e.g. photons, electrons, protons or
heavy ions. Even though protons and heavier charged particles offer preferable depth dose
characteristics, the majority of treatments are still performed with high energy photons.
Within this thesis only treatments with high energy photons are considered.
2.1 Course of radiotherapy
A typical radiation therapy treatment consists of a number of steps, of which an overview
is given in figure 2.1.
Imaging
of the patient
e.g. CT, MRI, PET
Delineation
of target and OARs
Planning
dose prescription
identification of
treatment parameters
Quality Assurance
plan verification
Dose delivery
fractionation
immobilization
image guidance
Figure 2.1: Overview of the workflow of radiation therapy.
To be able to deliver a high dose to the tumor the first step is the localization of the target
volume. 3D imaging modalities, e.g. computer tomography (CT), magnetic resonance
imaging (MRI) or positron emission tomography (PET) are used to obtain images of the
tumor. On these images the target and OARs are delineated for planning of the radiation
therapy treatment. The nomenclature used for target delineation is based on the ICRU
report [23],[22]. The gross tumor volume (GTV) is the macroscopic extent of the tumor, as
visible on the images. To account for microscopic tumor infiltration in the healthy tissue,
the clinical target volume (CTV) is delineated around the GTV. The internal target vol-
ume (ITV) encompasses CTV plus a margin to account for movements of the tumor. To
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account for positioning and other treatment technique related errors an additional margin
is added, resulting in the planning target volume (PTV).
The next step is to plan the therapy. In forward planning the treatment parameters such
as beam angle, field shape, field weight etc. are manually adjusted until the desired dose
distribution is obtained. For a good tumor control probability together with a low normal
tissue complication probability a high and homogeneous dose to the target and a low dose
to OARs and normal tissue are needed. For more complex radiation therapy techniques
with many degrees of freedom (DOF), forward planning does not result in optimal treat-
ment plans any more and inverse planning is performed. A detailed description of inverse
planning follows in section 2.3.
Another important issue in radiation therapy is quality assurance to ensure a safe and
correct delivery of the planned dose distribution. Therefore regular checks are performed
to test all functions of the linear accelerator (linac), e.g. the correct positioning of multi-
leaf collimator (MLC) leaves or dosimetric tests. Moreover measurements are carried out
to assure the feasibility to deliver the optimized treatment plan and to verify the dose
distribution calculated by the treatment planning software.
After all these steps to prepare the treatment the next step is the dose delivery. In most
cases the dose is not delivered in a single session but in a number of fractions. This is done
to improve the ratio of healthy to cancerous cells that survive the irradiation. Because
healthy cells have better repair mechanisms than cancerous cells, the time between two
fractions is used to remove reparable damage of healthy cells and thus increase the number
of surviving cells.
It is important that the patient is positioned during treatment exactly as during imaging.
Otherwise the high dose region would not hit the tumor but instead the OARs and there-
fore the patient would not be cured and instead suffer from side effects. To ensure the same
positioning the patient is immobilized for imaging and treatment. Modern image guided
radiation therapy techniques utilize imaging during the course of treatment to ensure the
correct positioning of the tumor during irradiation.
2.2 Treatment delivery techniques
For the treatment of a cancer patient with ionizing radiation different techniques are avail-
able. In brachytherapy the radiation source is inserted into the patient either inside or
very close to the tumor. This delivery method is not discussed in this thesis as the focus
is only on teletherapy techniques in which the radiation is delivered from a source outside
of the patient.
A common machine for the generation of high energy photons is a linear electron accel-
erator. As the name already suggests, electrons are accelerated on a linear path with
electromagnetic waves. After leaving the waveguide these high energy electrons are di-
rected onto a X-ray target, usually made of tungsten, where they interact and generate
bremsstrahlung photons. These photons pass through a primary fixed collimator which
determines the maximum field size of the radiation field. The next component is a beam
flattening filter which is designed to generate a uniform lateral dose profile. Basically,
this filter is a cone-shaped material that absorbs more radiation in the center of the field
and thus flattens the radiation field. Afterwards, secondary collimators such as jaws or
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a multi-leaf collimator (MLC) are used to form individual field shapes for the respective
treatment.
After entering a medium (e.g. a water phantom or the patient), the number of photons
in the tissue decreases exponentially with increasing depth of penetration (Lambert-Beer
law). The main interaction of photons in the energy range of 6 MV to 20 MV with tissue
is the Compton effect. The incoming photon is interacting mainly with electrons in the
tissue, thus transferring part of its energy to this electron. These secondary electrons then
pass their energy by Coulomb scattering to the tissue. This results in a depth dose curve,
as shown in figure 2.2, which is characterized by an initial build-up to a maximum dose
in the entrance region of the medium and then an exponential decrease with depth.
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Figure 2.2: Percentage depth dose curve for 6 MV photons.
The goal of radiation therapy is to deliver a high and homogeneous dose to the tumor
without delivering a high dose to organs at risk (OAR) or the normal tissue. Considering
the depth dose curves for photons this is not possible for deep seated tumors with a single
beam direction. Therefore, cancer treatment with photons employs several beam direc-
tions that overlap in the tumor volume. Rectangular fields from many beam directions
would lead to a cylindrical dose distribution around the tumor. Since tumor shapes are
quite complex in most cases, the next step is to conform the field shape to the contour of
the tumor. For shaping the radiation fields MLCs might be used. MLCs consist of metallic
plates, so called leaves, that can block the radiation field. The leaves are arranged in two
opposing banks and each leaf can move independently.
With this conformal radiation therapy (CRT) technique, it is not possible to shape the
dose distribution exactly to concave indentations in the target volume. The solution to this
problem is to use intensity-modulated techniques. In IMRT, non-uniform fluence fields are
used to conform the dose distribution closely to the volume of the tumor. This technique
was proposed by Brahme in 1982 [9]. Since the first IMRT treatment 15 years ago in
Houston, Texas, many different intensity-modulated techniques were developed and are
frequently-used in clinical routine. A review on IMRT can be found in [7]. In the following
section, an overview of different intensity-modulated treatment techniques is given.
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2.2.1 Fixed-field intensity-modulated radiation therapy
Fixed field techniques are characterized by a static radiation source during irradiation.
The number of beam directions for fixed field IMRT might vary for different treatment
modalities and also treatment times vary in a wide range depending on the complexity
of the respective case. For the two techniques described in this section the number of
beam directions typically varies between 5 and 9 beams. An example of a dose delivery
technique that uses more beam directions is the cyberknife (Referenz). The cyberknife
is a robotic system equipped with a compact 6 MV linac which can irradiate the tumor
from arbitrary beam directions with circular fields of different sizes. Here, two widely
used techniques are described that are performed with a conventional linac equipped with
a MLC.
Step-and-shoot IMRT
In Step-and-shoot IMRT a sequencing algorithm is used to translate the optimized fluence
profile into a set of deliverable fluence fields with different weights and shapes, so called
segments. The superposition of all these segments adds up to the desired fluence profile.
During dose delivery, a MLC is used to block radiation outside the field shape. After
all leaves were positioned correctly, the radiation is switched on to deliver the number of
monitor units determined for the first segment. This is repeated for all segments from
all beam directions. Therefore, the treatment time depends on the number of segments.
The more segments are used, the closer the superposition of all segments matches the
optimized non-uniform fluence field, but also the treatment time increases. Moreover the
scatter radiation to the patient increases if more segments are used, which leads to a higher
integral dose in the patient.
Dynamic IMRT
In dynamic IMRT the leaves of the MLC are moved during irradiation. To deliver the
optimized fluence profile, the speed of the leaves varies while they cross the radiation
field. If the gradient of the fluence profile is positive, the leading leaf is moving with the
maximum achievable speed and the trailing leaf is used for fluence modulation. The speed
of both leaves can be calculated according to the Stein equations [53]:
I ′(x) ≥ 0 : vL(x) = vmax and vT (x) =
vmax
1 + vmax ∗ I ′(x)
I ′(x) < 0 : vT (x) = vmax and vL(x) =
vmax
1− vmax ∗ I ′(x)
The treatment time needed for dynamic IMRT depends on the maximum speed of the
MLC leaves.
2.2.2 Dynamic rotational treatment techniques
In rotational therapy techniques the radiation source moves around the patient during
dose delivery. The large number of beam directions allows for delivery of highly conformal
dose distributions. Compared to fixed field techniques, the dose to the normal tissue is
spread over a larger volume.
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Tomotherapy
The concept for tomotherapy was introduced in 1993 [29]. This technique employs a
rotating fan beam to deliver the dose to the patient. To modulate the dose delivery a
fast, pneumatically driven binary collimator is used. In serial tomotherapy the patient is
shifted for the width of the fan beam after each rotation of the radiation source. So the
dose distribution is made up of dose slices delivered to the patient, which explains the
name tomotherapy which literally means ”slice therapy”.
Serial tomotherapy was the first IMRT technique, with its first patient treatment in 1994
in Houston, Texas. The dose delivery in slices bears the risk of an under- or overdosage
between the slices if the patient positioning is not absolutely correct. Moreover, the
treatment time for this technique is very long. To solve these helical tomotherapy was
developed. In this technique the patient is moved through the gantry bore while the
radiation source rotates, resulting in a helical dose application. For helical tomotherapy a
specifically designed treatment machine is necessary, which has been available for clinical
use since 2002.
Arc therapy
Arc therapy is performed with a conventional C-arm shaped linear accelerator. The dose
is delivered by rotational cone beams of varying shapes. The idea for arc therapy with
dynamic field shaping was first described in 1965 by Takahashi, called conformation radio-
therapy. Instead of using fields with a predefined width, the shape of the fields conforms
to the shape of the treatment volume [58].
To achieve dose distributions with conformalilty equal to that of IMRT or tomotherapy,
Yu proposed in 1995 intensity-modulated arc therapy (IMAT) [75]. In IMAT, dose deliv-
ery is performed in several superimposing arcs. Each arc can have a different weighting
factor, but within one arc the dose rate is constant. The shape of each aperture can vary
within the limitations set by the MLC during dose delivery.
Since treatment times for IMAT are long and the treatment planning process is com-
plicated, IMAT was not widely used in clinics. An idea was proposed to decrease the
treatment time by the delivery of the complete dose in a single rotation of the gantry
with variable dose rate and/or gantry speed. The first paper showing the feasibility of
this approach to achieve conformal dose distributions was published in 2005 [10]. At the
same time, the optimization algorithm presented in this work was developed and pub-
lished in 2006 [59], [61]. Recently, many approaches for single arc therapy optimization
were proposed, some of them will be reviewed in section 2.3.2. The clinical implemen-
tation of single arc techniques started in 2008. The first commercially available system
was advertised with the trade name RapidArcTM by Varian and is in clinical use since
January 2008 [1]. Not long after the announcement of RapidArcTM Elekta also marketed
a product with dynamic MLC and variable dose rate named VMATTM . By now there is
a wide adoption of these techniques for the treatment of cancer patients. Throughout this
thesis, arc-modulated cone beam therapy (AMCBT) will be used as acronym for dynamic
rotational therapy with variable dose rate.
Reasons for the fast implementation of single arc techniques into clinics are presumably
the fast treatment times together with the ability to deliver highly conformal dose dis-
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tributions. Compared to helical tomotherapy, arc therapy has the advantage that it is
performed with a conventional linac, and therefore it is possible to use the same treatment
unit for different treatment techniques. The use of a conventional linac also offers the
possibility to use non-coplanar beams.
2.3 Inverse treatment planning and dose optimization
2.3.1 Principle of inverse planning for IMRT
Inverse treatment planning was developed for the optimization of treatment plans for com-
plex treatment techniques that employ many degrees of freedom. Before the invention of
intensity-modulated radiotherapy, the degrees of freedom for therapy planning were the
beam directions, the field shapes and field weights. Manual adjustment of these parame-
ters to find an acceptable dose distribution was possible within a reasonable time. With
IMRT, the number of DOF is rapidly increased by adding the flexibility to vary the fluence
from each beam direction. The fluence field is subdivided into so called bixels and the
weight of each bixel can have an arbitrary weighting factor. The total number of DOF is
the number of beam directions times the number of bixels per beam. Depending on the
size of the bixels and the size of the target volume, the number of DOFs is in the order of
several hundred and therefore it is not feasible to adjust the plan parameters manually.
In inverse planning, the order of planning is interchanged: instead of adjusting the treat-
ment parameters by a trial and error process to get an acceptable dose distribution, the
user specifies dose constraints and an inverse planning program is used to find the treat-
ment parameters which result in a dose distribution that most closely matches the given
constraints. A review of inverse planning can be found in [72].
For this work the research version of the inverse planning system KonRad was used [37]
[39] [38]. Therefore, the explanations given in this section are oriented towards the imple-
mentation of the KonRad inverse planning software. Other inverse planning systems may
adopt different parameters to specify the desired dose distribution (i.e. biological objec-
tives instead of physical dose objectives), other measures to define the difference between
the actual and the planned dose constraints or other optimization algorithms.
The basic information required by KonRad for treatment planning is a CT image of the
patient anatomy with contoured volumes of interest (VOI). The three dimensional data
set of the patient is divided into voxels with a resolution of 2.62 mm3 and each voxel is
allocated to a specific VOI. Based on this data, a pencil beam algorithm is used to deter-
mine the dose matrices Dkij for the predefined field shapes Zk irradiated with a uniform
fluence. The element Dkij of this matrix stores the dose that is deposited in voxel i by
bixel j from beam direction k for unit fluence. The total dose di in voxel i from the field
shapes Zk of all beam directions contributing with the bixel weights wjk is given by:
di =
Nk∑
k=1
Njk∑
j=1
Dkijwjk
withNk the number of beam directions andNjk the number of bixels j from beam direction
k.
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The first step in inverse planning is the definition of dose constraints. In KonRad, for
each VOI a minimum and a maximum constraint is defined as well as a penalty factor
that determines the importance of this constraint. For organs at risk the minimum dose
constraint is set to 0. These standard dose constraints can be formulated in terms of a
‘prescribed‘ dose dpresi and a penalty factor si for each voxel i as:
dpresi =


dmaxV OI
dminV OI
di
, si =


smaxV OI if di > d
max
V OI
sminV OI if di < d
min
V OI
1 if dminV OI < di < d
max
V OI
The goal of the optimization process is the minimization of an objective function. The
objective function in KonRad is a weighted sum of the square of the deviations from the
given constraints:
F =
Ni∑
i
si(di − d
pres
i )
2
here Ni is the number of considered voxels.
Standard 2-step planning approach
The standard approach for IMRT planning consists of two steps: (1) Optimization of the
bixel weights, followed by (2) sequencing the fluence profiles into deliverable MLC seg-
ments.
projection
calculation of new
bixel weights
backprojection
dose calculuation
evaluation
objective function STOP?
Figure 2.3: Optimization loop
In this approach the bixel weights are the parameters that are varied to minimize the dif-
ference between the actual dose distribution and the predefined treatment goals. The only
constraint on the weights for a physically feasible solution is that all fluence weights need
to be positive. For the optimization of bixel weights, different optimization algorithms
were proposed and reported in the literature, most of them iterative search algorithms.
For this work a modified Newton-gradient method was used [37]. The flowchart in figure
2.3 shows the optimization cycle. Based on the mathematical optimization method used
for treatment planning a new set of bixel weights wjk is calculated (projection). In the
next step the dose di in each voxel i is calculated for the new set of bixel weights (back-
projection). In the last step the new dose distribution is evaluated with the objective
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function. If any pre-defined abort criterion is fulfilled the optimization stops, otherwise a
new set of bixel weights is calculated.
The result from this optimization is a fluence map for each beam direction used for treat-
ment planning. There is not a single set of fluence maps that represents the optimal
solution, but due to the degeneracy of the related inverse planning problem there are a
number of different fluence maps that lead to almost the same dose distribution. During
the optimization the fluence weights can have arbitrary values. For the delivery of a treat-
ment plan it is necessary to convert these optimized fluence maps into a set of deliverable
apertures. Based on the number of intensity levels allowed in the final fluence distribution,
the bixel weights are modified to fixed values (stratification) and with a leaf-sequencing
algorithm translated into deliverable beam segments.
This second step can lead to a degradation of the dose distribution quality that was
achieved during the optimization process. The stratification of the bixel weights causes a
change of the optimized fluence map and therefore a change in the final dose distribution.
Different attempts have been made to reduce the complexity of a fluence distribution, e.g.
setting intensity limits or applying smoothing filters.
Direct aperture optimization
A single step treatment planning method was proposed in 2002 [50], called direct aperture
optimization (DAO). Instead of optimizing the bixel weights, the segment weights and
shapes are optimized. This approach directly generates a deliverable treatment plan and
thus eliminates the sequencing step. Since the number of segments per beam direction
is chosen prior to the optimization the user can control the complexity of the treatment
plan.
It was shown in several studies comparing DAO and 2-step planning for IMRT, that the
number of segments and also the number of monitor units can be significantly reduced
with DAO [51], [17], [66], [3], [13], [24].
2.3.2 Optimization concepts for arc therapy with variable dose rate
The first publication of an optimization concept for arc therapy with a variable dose rate
was published in 2005. In the last four years there were a number of publications of
different optimization approaches for this dose delivery technique, but not all of them
will be reviewed here. The optimization concepts of the first three publications on this
topic are based on a DAO algorithm, as described in the sections on sweeping window
arc therapy, arc-modulated cone beam therapy and volumetric modulated arc therapy. To
show the alternative of a 2-step planning approach for single arc therapy the concept of
arc-modulated radiation therapy is also introduced.
Sweeping window arc therapy
The concept of sweeping-window arc therapy (SWAT) was developed for the optimization
of treatment plans for IMAT, but with the ability to vary the dose rate during rotation [10].
For the optimization, a direct aperture optimization is used that optimizes the field shapes
with simulated annealing and the weights are calculated analytically. The name SWAT
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originates from the initialization of the field shapes: a leaf sequence of sweeping windows
that move back and forth across the target as the gantry rotates. Target conformal fields
are not close to an optimal solution and therefore a successful optimization starting with
target conformal fields is difficult. By imposing more variation in the field shapes it was
shown that a successful optimization of dose distributions is possible.
Arc-modulated cone beam therapy
Arc-modulated cone beam therapy (AMCBT) is the optimization algorithm that was
developed during this project. A detailed description of the algorithm follows in chapter
3. The optimization concept is also based on a direct optimization of field shapes and
field weights. The main differences to other optimization algorithms are the choice of the
initial solution and the use of a tabu search algorithm to optimize the field shapes [61].
Volumetric modulated arc therapy
The key feature of the algorithm for inverse planning of volumetric modulated arc therapy
(VMAT) [40] is the increasing angular sampling rate during the optimization. At the be-
ginning of the optimization only a few beam directions (or control points) are included in
the optimization. For these control points the field shapes and weights are optimized with
a stochastic algorithm that is similar to simulated annealing. Since the angular interval
between two consecutive control points is large, the restrictions imposed by the hardware
are not severe. Moreover the algorithm converges faster because of the limited number of
DOF. After a predefined number of iterations, the number of control points is doubled.
This increases the dose modeling accuracy during the optimization.
The treatment planning software used for RapidArcTM (Varian) is based on this optimiza-
tion algorithm.
Arc-modulated radiation therapy
This approach for the optimization of single arc treatments was proposed by Wang in 2008
[71]. In contrast to the approaches described so far this algorithm is not a direct aperture
optimization but uses a two step approach similar to conventional IMRT planning. The
first step is an optimization of the fluence profiles for a fixed number of beam directions,
e.g. separated by 10◦. In this optimization no hardware restrictions are considered and
therefore the resulting dose distribution is of the same quality that any IMRT plan could
possibly achieve. In conventional IMRT planning the leaf sequencing step is used to find
aperture shapes that closely match the ideal intensity profile. In AMRT the focus is on
finding apertures that can deliver the same dose as the optimized intensity pattern. With
graph algorithms an optimal set of aperture shapes is calculated considering restrictions
given by the maximal speed of the MLC leaves. In a post-optimization step the weights
of the apertures for each beam angle are determined based on a least-square optimization.
For the next step the following assumption was made: the dose delivered from a given
intensity profile at a fixed gantry angle could also be delivered through apertures from
neighboring beam angles. The stack of apertures at a fixed angle is moved to neighboring
angles and a geometrical adjustment of the shifted aperture shapes is performed.
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2.4 Challenges in high precision radiotherapy
The description of the radiotherapy workflow in section 2.1 gives an overview of issues that
are important for a successful treatment and the last two sections reviewed in more detail
treatment delivery and inverse planning. High-precision radiation therapy is only possible
if all essential steps in the course of the treatment are performed accurately. For example,
the better dose shaping capabilities of modern dose delivery techniques also require a more
exact localization of the tumor.
The first source of error in the localization of the tumor occurs in the delineation of the
target. Even though developments in imaging have improved the quality of images there
are still uncertainties in the exact delineation of the target. Several studies were performed
to compare the delineation of a target on the same image data by different physicians.
These studies showed a large inter observer variability in the delineation, e.g. a recent
study on lung cancer patients [70].
Another issue that needs to be considered in high-precision radiation therapy is motion
of the target or deformations of the patient anatomy during the course of treatment. For
example, tumors in the lung might move due to respiration or in prostate cancer the posi-
tion of the tumor depends on the filling of the bladder. Motion of the tumor during dose
delivery is called intra-fraction motion and between two radiation fractions it is called
inter-fraction motion. To detect changes in the patient anatomy between two fractions an
image of the patient prior to each treatment could be performed. For this purpose in-room
CTs or imaging devices included in the medical linear accelerator, e.g. kV or MV cone
beam CTs, could be used. A possible disadvantage of imaging the patient each day is the
additional dose that is delivered to the patient.
There are various approaches to account for motion during dose delivery and this is cur-
rently an active research area. It would go beyond the scope of this work to give a detailed
overview of motion effects in radiotherapy and techniques to account therefore, a review
can be found in [73]. As one possibility to account for motion the concept of tumor track-
ing should be introduced here. The idea of tumor tracking is to follow the movements
of the target with the irradiation beam during dose delivery. Therefore it is necessary
to monitor the target during irradiation. This could, for example, be done with x-ray
imaging (MV or kV), with electromagnetic transponders implanted in the tumor (e.g. Ca-
lypso beacons), or with optical imaging of the patient surface (e.g. ExacTrac, BrainLab or
RPM (real-time position monitor), Varian). If the position of the tumor changes during
treatment, the radiation field moves to follow the movement of the target.
The improved dose shaping capabilities that are possible due to the large number of degrees
of freedom also lead to drawbacks in the dose delivery. The field sizes used for irradiation
in IMRT are much smaller than for conventional techniques, and thus the ratio of MUs
per Gy is higher than for conventional techniques. This leads to an increase in leakage
radiation and the patient receives more scattered radiation. This widespread additional
dose might cause radiation-induced secondary cancer.
Another disadvantage of fixed field IMRT or tomotherapy compared to conventional treat-
ment techniques is the increase in treatment time. This leads to a decrease in the number
of patients that could be treated at one treatment machine. For the patient it implies a
longer time on the treatment couch and movements might occur more often.
3 Optimization concept for
arc-modulated cone beam therapy
This chapter deals with the optimization concept for AMCBT. The first implementation
of this concept was accomplished during my diploma thesis and is reported in [59]. The
optimization for AMCBT has been integrated into the research version of the inverse
planning system KonRad [39]. In section 3.1 the algorithm is described including several
enhancements made during the course of the PhD. The most important extension of the
algorithm was the inclusion of constraints that are imposed by the delivery hardware.
Section 3.2 describes which hardware constraints are important for rotation therapy, how
they were considered in the frame of the optimization and how they influence the dose
distribution.
3.1 The optimization concept
The degrees of freedom (DOF) for the optimization are the field shapes Zk and the beam
weights wk for a predefined number of beam directions Nk. The field shapes are made up
of small beam elements called bixels j, i.e. Zk = {j|j is an open bixel from beam direction
k}. Altogether the number of DOFs is in the same order of magnitude as for an IMRT
optimization.
The explanations given in section 2.3 for dose calculation and dose prescription for IMRT
are the same for AMCBT. In contrast to standard IMRT all bixels from one beam direction
k will have the same weight for AMCBT: wjk → wk. This leads to a simplification in the
matrix multiplication needed to calculate the dose in each voxel i. The dose contribution
in voxel i from field shape Zk is the sum of the dose values from all respective bixels j:
Di(Zk) =
∑
j∈Zk
Dkij
The total dose di in voxel i is then:
di =
Nk∑
k=1
Di(Zk)wk
The bixel concept is used to have a fast method to update the dose distribution after
changing the field shapes or beam weights. The disadvantage of this approach is that it
is only possible to alter the field shapes in steps of at least one bixel. The other set of
variables, the beam weights, can have arbitrary positive values.
During the optimization the objective function F is minimized:
F =
Ni∑
i
si(di − d
pres
i )
2
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In the following sections the new optimization concept is introduced step by step. The first
section describes the generation of the initial field shapes. Next, the optimization loop is
introduced by first explaining the optimization of the beam weights and the field shapes
separately. At the end of section 3.1.2 both methods are combined to one optimization
loop for the beam weights and the field shapes.
3.1.1 Automated generation of initial field shapes
A key feature of this algorithm is the selection of the initial set of field shapes Zk. Target
conformal field shapes usually lead to unnecessarily long optimization times and to solu-
tions of limited quality. Therefore the OARs are already considered in the generation of
the initial field shapes.
A
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k
and Bk A
(1)
k
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(1)
k1
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k
A
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A
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k
Figure 3.1: Generation of the initial field shapes: On the left side of the figure the pro-
jections of the target(grey) and an OAR(dashed) to the isocenter plane are shown together
with the bixel grid. The method by which the initial field shapes are determined from these
projections is explained in the text.
Figure 3.1 shows how the initial field shapes are determined from the projection of the
target and an OAR to the isocenter plane. The bixels that are covered by the projection
of the target are shown in grey and the ones for the projection of the OAR are labeled by
dashed lines. All bixels that belong to the target are included in the bixel set A
(0)
k , the
bixels in the projection of the OAR in the set Bk. The first step is to open all bixels that
belong to A
(0)
k , except the ones that belong to Bk, i.e.,
A
(1)
k = A
(0)
k − (A
(0)
k ∩Bk)
If this set of bixels is not continuously connected, e.g. A
(1)
k = A
(1)
k1
+A
(1)
k2
, it is not possible
to shape this field with an MLC. In this case all subsets A
(1)
ki
that are smaller than a
predefined number Nc of bixels are closed. If there are still more subsets than one, only
the first subset A
(1)
k1
is opened:
A
(2)
k = A
(1)
k1
In this case, only one part of the tumor volume is irradiated. After a gantry rotation
of 180◦, the projections of the target and the OAR will look very similar, and then the
remaining part of the tumor is irradiated. So after a full rotation of the gantry a homo-
geneous dose distribution in the tumor volume usually can be achieved.
The thus determined bixel set A
(2)
k as initial field shape would naturally lead to low doses
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in the target volume next to the OAR. Therefore some additional bixels are opened. Start-
ing from A
(2)
k the algorithm checks which adjacent bixels belong to A
(0)
k and adds them
to the set A
(2+)
k . This could be performed by adding more classes of neighboring bixels
which creates the corresponding bixel sets A
(2++)
k , A
(2+++)
k and so on. The initial field
shapes Zk consist of all bixels that belong e.g. to the set A
(2++)
k :
Zk = {j|j ∈ A
(2++)
k }
How many additional bixels are needed clearly depends on the size of the bixels, the ge-
ometry of the patient anatomy and the beam quality of the employed treatment modality.
The approach to spare OARs from dose with the initial fields is only useful if the geometri-
cal projections of the OARs separate the target volume for at least some beam directions.
Example beam´s eye view (BEV) projections of different patient geometries are shown in
figure 3.2.
(a) prostate (b) head and neck (c) anal
Figure 3.2: Beams Eye View of different tumor types.
For the prostate case, the rectum is separating the tumor in two separate BEV projections
and was therefore used for the generation of the initial field shapes. In case of the head
and neck tumors this role was assigned to a combination of brain stem and spinal cord.
To employ, for example, the parotids as the separating OAR for initial field generation
does not help the algorithm to find a better and faster solution. For the anal carcinoma
cases there are no OARs that naturally separate the target volume in the BEV for any
beam direction. Therefore help VOIs might be generated for the generation of the initial
field shapes.
A boost volume is a challenge for arc therapy, because the fluence is not modulated within
one field and therefore it is complicated to have two dose levels within one arc. To improve
the dose gradient between PTV and boost, the boost volume might also be considered in
the generation of the initial set of field shapes. To give an example, for some beam di-
rections, e.g. all beams in the angular interval between 310◦ and 360◦ gantry angle, only
bixels covering the boost (and not the PTV) might be opened in the initial field shapes.
3.1.2 Optimization loop
The optimization loop starts after the calculation of the dose matrices for the initial field
shapes Zk. At first the beam weights wk are optimized for these field shapes with a
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gradient algorithm until a stopping criteria is fulfilled. Then the tabu search algorithm,
which optimizes the field shapes, starts.
initial solution x0 = {Zk, wk},
xbest = x0, F (xbest) = F (x0)
generate neighbourhood
calculate objective values
select best neighbour
best neighbour taboo ?
no
yes
delete best
neighbour
F (xn) ≤ F (xbest) ?
yes
no
xbest = xn
F (xbest) = F (xn)
stop?
yes
display best solution xbest
no
save xn−1 in T
k++
n++
Figure 3.3: Flowchart of the tabu search algorithm, which is used to optimize the field
shapes. All steps are explained in the text.
Optimization of beam weights
The first optimization loop is a modified Newton gradient method to optimize the beam
weights wk for a given set of field shapes [6]. This gradient algorithm is commonly used
for the optimization of treatment plans for IMRT. It was already implemented in the
treatment planning system KonRad to optimize the bixel weights for an IMRT treatment,
so only minor changes were necessary to use it for AMCBT.
After the generation of the initial field shapes this gradient algorithm is called for the first
time. Optimization of field weights is performed until the percentage difference between
the current and the previous objective function value is smaller than a predefined threshold.
Later on it is combined with the tabu search algorithm to optimize the beam weights
together with the field shapes.
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Optimization of field shapes
The optimization of the field shapes is not possible with a gradient algorithm, because the
search space is not convex. To overcome local minima a tabu search algorithm was used.
Tabu search is an iterative neighborhood method that was developed by Glover [19] in
1986. In this subsection the implementation of the algorithm for the optimization of the
field shapes is described. An overview of the procedure is given in figure 3.3.
The input data for the tabu search is the initial solution x0 = {Zk, wk}, which is the
set of the initial field shapes Zk and the optimized beam weights wk. The optimal set
xbest is determined by an iterative approach where xn represents the solution derived in
iteration n. The beam weights wk are not changed in this part of the optimization loop
and therefore are not considered explicitly.
The initial solution x0 and the value of the objective function F (x0) are stored as best
solution xbest = x0 and best objective value F (xbest).
Generation of neighborhood
The first step in the tabu search is the generation of the so called ”neighborhood” of one
single field shape Zl at angle l. In general, the neighborhood N(Zk) of a field shape Zk
consists of all field shapes N±j(Zk) which have one additional bixel j opened or closed at
the edge of the field, i.e.
N±j(Zk) = Zk ± j
The plus or minus sign indicates whether the bixel j was opened or closed.
To create a neighbor one leaf of the MLC must be opened or closed for one bixel width. As
an example, figure 3.4 shows a field shape and four neighbors of this field. The maximum
number of neighbors is four times the number of open leaf pairs, but usually the number
is lower because a field shape can only be enlarged if the dose matrix of the adjacent bixel
was calculated. In the first iteration the number of neighbors is only twice the number of
leaf pairs, because no dose matrix outside the initial field shapes is calculated.
   
field shape Zk N+31(Zk) N−32(Zk) N+35(Zk) N−34(Zk)
0 1 3 4 5
11
1213
18
24 2829
3031 35
Figure 3.4: Generation of a neighborhood. On the left side an arbitrary field shape Zk
is shown together with the bixel numbers. The other four pictures show neighbors of this
field shape, the changed bixel is highlighted in red.
Ranking of new neighborhood field shapes
The next step in the tabu algorithm is the calculation of the objective function for each
neighbor. By opening or closing a bixel j, the dose information for the field shape changes:
Di(N±j(Zk)) = Di(Zk)±D
k
ij
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Thus the dose di in some voxels is different and the value of the objective function changes
accordingly. A calculation of the objective function for many neighbors is very time con-
suming, therefore only the difference from the actual objective function F (x0) is calculated
and added to F (x0). This is only possible if we assume that the weights of the beams wk
do not change.
In this calculation only the dose values for voxels which are influenced by the opened or
closed bixel j from beam direction k are recalculated:
dnewi = d
old
i ±D
k
ijwk
The dose value di is changed in all voxels i with D
k
ij 6= 0. These voxels are indicated with i
′
in the following. The new value of the objective function is then determined by subtracting
the old contributions from the changed voxels and adding the new contributions of these
voxels to the old objective function F (xn−1) = F ({Z1, ..., Zl, ..., ZN ;w1, ......, wN}).
F ({Z1, ..., N±j(Zl), ..., ZN ;w1, ......, wN}) = F ({Z1, ..., Zl, ..., ZN ;w1, ......, wN}) + ∆F
with
∆F =
∑
i′
snewi′ (d
new
i′ − d
pres,new
i′ )
2 −
∑
i′
soldi′ (d
old
i′ − d
pres,old
i′ )
2
The result of the first two steps in the tabu search is the neighborhood N(Zl) of the field
shape Zl and the corresponding values of the objective function
F ({Z1, ..., N±j(Zl), ..., ZN ;w1, ......, wN}):
N(Zl) = {N±j(Zl)}
Selection of a non-tabu new field shape
In the next step the best neighbor Nbest(Zl) - that means the one with the lowest objective
value F ({Z1, ..., N±j(Zl), ..., ZN ;w1, ......, wN})- is selected from the neighborhood N(Zl).
The new solution xn consists of the same field shapes Zk and weights wk like the last
solution xn−1, except for the field shape Zl which is substituted by Nbest(Zl). Next, the
algorithm checks if the new solution xn is in the tabu list. The tabu list T contains all
solutions that were visited in the last t iterations, here t denotes the maximum length of
the tabu list:
T = {xn|nact − n < t}
with nact the number of already performed iterations. If less than t iterations were per-
formed yet, the length of the tabu list is nact.
If a solution is already contained in the tabu list it is not allowed to be visited again, thus
the solution is said to be ”taboo”. The purpose of this list is to prevent the algorithm from
oscillating between a few solutions. The algorithm allows solutions with a higher value of
the objective function in order to escape from local minima in the non-convex objective
function. However, an unlimited tabu list bears the risk that the algorithm can not find
the global minimum because too many restrictions block the way to the optimum.
If the neighbor for one iteration is tabu, it is deleted from the neighborhood and the second
best neighbor is chosen. The first neighbor that is not tabu is selected as the new field
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shape at angle l.
Next, for the new solution xn with field shape Nbest(Zl) instead of Zl, the objective func-
tion is calculated. If this value is lower than the best one so far, xn is stored as the best
solution xbest.
If no exit condition is met, the last solution xn−1 is stored in the tabu list and the neigh-
borhood of the next field shape is calculated. After changing one bixel in all field shapes Zk
the algorithm starts again with changing one bixel in the first field shape until a stopping
criteria is fulfilled.
Optimization of beam weights and leaf positions
So far the optimization of the beam weights and the leaf positions has been discussed
separately. But the optimal beam weights wk will change by optimizing the field shapes
and thus both classes of DOFs need to be considered during the optimization loop. The
modification of one bixel in one field shape does not change the beam weights wk very
much. That is why we could use the fast method to calculate the objective functions
for the neighbors. But as more field shapes are changed the beam weights will begin to
deviate from the new optimal weight factors.
The combination of both optimization loops is shown in figure 3.5. Starting with the
initial field shapes Zk and optimized beam weights wk the tabu algorithm is used to find
the best solution in the neighborhood of the field shape from the first beam direction.
The new solution xn is generated from the last solution xn−1 by replacing the old field
shape Zk with the new one Nbest(Zk), even if this leads to a higher value of the objective
function.
As already mentioned, the beam weights do not change very much with the modification
of one field shape. For this reason the next three steps are not obligatory for each iter-
ation step as indicated also in figure 3.5. But after modifying several field shapes, the
difference between the optimal beam weights and the actual beam weights will increase
and a recalculation is required.
Before the start of the optimization process the user has to schedule how often the beam
weights should be recalculated, e.g., in every p-th step of the iteration. Moreover it is
possible to define the number of gradient optimization iteration steps q, e.g. p = 3 and
q = 4 means a recalculation of beam weights wk in every third iteration with four gradient
iteration steps for the beam weight optimization.
The next step in the optimization loop is the query if the actual value of the objective
function F (xn) is lower than the best one F (xbest). If this is true, the actual solution is
stored as the best one. In this case the counter for the number of iterations since the last
improvement nbest is set to zero. Otherwise nbest is incremented.
The optimization stops if either a maximum number of iterations nmax was performed,
or the algorithm did not find a better solution for more than nmaxbest iterations. If one of
the stopping conditions is met, the algorithm stores the optimal field shapes and weight-
ing factors. Otherwise the number of iterations n is incremented and the tabu algorithm
searches for the best bixel in the next field shape.
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initial solution x0,
xbest = x0, F (xbest) = F (x0)
Tabu search
solution xn = Nbest(Zk)
F (xn) = F ({Z1..Nbest(Zk)..ZN ;wk})
calculate new beam weights wk
calculate new dose distribution di
calculate objective function F (xn)
F (xn) < F (xbest)?
yes
nbest = 0
no
nbest++
xbest = xn
F (xbest) = F (xn)
nbest > n
max
best
or n > nmax ?
yes
display best solution xbest
no
iteration n++
beam direction k++
q
p
Figure 3.5: Optimization loop for AMCBT. It is shown how the tabu search (field shapes)
and the gradient algorithm (beam weights) are working together. All steps are explained
in the text.
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3.2 Hardware limitations
In the last section the limitations that are imposed by the hardware were not considered
during the optimization process. The hardware limitations for dynamic arc therapy are:
• the rotation speed of the gantry
• the dose rate of the accelerator
– minimum and maximum dose rate
– maximum variation of the dose rate
• and the maximum leaf speed of the MLC
For AMCBT the gantry rotation speed is assumed to be constant for a single treatment,
but it can change for different cases. Since the other constraints depend on the rotation
speed of the gantry - e.g. a faster rotation speed results in less time for the leaves to
move between consecutive angles - this value is determined first in the optimization. The
initialization of the optimization starts without constraints - the initial field shapes are
generated according to the description in 3.1.1 and the optimization of the beam weights
for these shapes is performed until the first stopping criteria is fulfilled. At this point
in the optimization the ”optimal” gantry rotation speed for the treatment is determined.
The field weights comply with the number of monitor units for a 10*10 cm field, but also
for irregular field shapes, as present for AMCBT, an estimation of the number of MUs
from the field weights is possible. With this approximated number of MUs per beam a
mean value MU beammean of the number of MUs per beam could be calculated. Taking also
the mean dose rate DRmean =
DRmin+DRmax
2 of the linac into account, the gantry rotation
speed is calculated according to the following formula:
vgantry =
DRmean
MU beammean
∗
ϕstop − ϕstart
Nbeams
with ϕstart, ϕstop the start and stop angle of the gantry rotation and Nbeams the number of
beams. If the calculated gantry rotation speed exceeds the limitations physically achiev-
able with the employed hardware, it is set to the respective value.
There are several assumptions that led to this approach to consider the hardware con-
straints, however it is not claimed that this approach is the best one. The reason to
choose the number of monitor units instead of the maximum leaf travel distance to deter-
mine the gantry rotation speed is based on a study of how hardware limitations influence
the quality of the dose distribution. As shown in the results of section 5.1, for AM-
CBT with the hardware constraints that are based on the performance characteristics of
a Siemens ArtiseTM linac equipped with a 160MLCTM , it was seen that only the dose
rate constraints led to a degradation of the plan quality. Therefore, the rotation speed
was chosen as to best match the requirements of the respective plan on the dose rate. To
simplify the insertion of hardware constraints into the optimization concept the gantry
rotation speed is kept constant for the optimization. Moreover the beam directions are
assumed to be evenly spaced between the start and stop angle.
After fixing the gantry rotation speed, the calculation of all other limitations that need
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to be considered during the optimization process is straightforward. The time between
consecutive apertures is:
tfield =
ϕstop − ϕstart
NBeams ∗ vGantry
With the minimum (DRmin) and the maximum dose rate (DRmax) of the linac the number
of MUs or the field weight, respectively, are determined:
MUfieldmin = DRmin ∗ tfield
MUfieldmax = DRmax ∗ tfield
The maximum change of the number of monitor units between consecutive beam directions
is:
MUchange = DRchange ∗ t
2
field
with DRchange being the maximum achievable change of the dose rate per minute. The
limitations of the beam weights were included into the backprojection of the gradient
algorithm. If any beam weight exceeds the maximum or minimum value, it is set to
the respective value. If the difference between the beam weights of the actual beam and
the former beam is more than MUchange, the new weight is modified to stay within the
limitations.
The last hardware limitation that needs to be considered is imposed by the MLC that
is used to shape the radiation fields. With the gantry speed vgantry and the maximum
physical achievable leaf speed vleaf of the MLC, the maximum distance that the leaves
can move between consecutive beam directions is:
xLeaf = vLeaf ∗ tfield
Since this limitation was not considered in the generation of the initial field shapes the
first step is to detect all leaf positions that violate this constraint. Therefore consecutive
apertures are compared and if for any leaf the distance of the movement is too large both
apertures are changed to fulfill the constraint. If possible, the leaf positions that are too
far apart are moved towards each other. If this would lead to a violation of the limita-
tion with the neighboring apertures, only the aperture shape that stays within the limits
is changed. During the optimization all changes which violate the MLC limitations are
rejected.
A flowchart summarizing the insertion of hardware constraints into the optimization con-
cept for AMCBT is shown in figure 3.6.
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Figure 3.6: Flowchart of the optimization algorithm with the inclusion of hardware limi-
tations.
4 Treatment plan comparisons
In this chapter the dose distribution quality that is achievable with arc-modulated cone
beam therapy is examined. For different tumor sites single arc treatment plans are com-
pared to fixed-field IMRT and helical tomotherapy plans and the advantages and disad-
vantages of the techniques are discussed. Moreover, a comparison of AMCBT and an
”idealized IMRT” technique is performed to investigate possible dosimetric advantages of
arc therapy in several rotations (section 4.3).
Since the clinical implementation of single arc techniques several treatment plan compar-
ison were published. Studies have shown a good plan quality for prostate tumors [42],
benign intracranial tumors [16] and tumors of the cervix uteri [11]. The investigation
of prostate carcinoma cases showed a more favorable dose distribution for VMAT with a
variable dose rate compared to five-field IMRT or VMAT with a constant dose rate. More-
over, the number of MUs was lower for VMAT compared to IMRT. The plan comparison
for small intracranial tumors with a mean PTV volume of 4.22 cm3 showed a similar
target coverage and sparing of OARs. The conformity index, CI95, for RapidArc
TM was
lower compared to IMRT and higher compared to helical tomotherapy. The integral dose
for RapidArcTM was higher compared to IMRT, but lower compared to tomotherapy.
The comparison for cervix uteri radiotherapy between RapidArcTM and fixed field IMRT
showed an improved sparing of OARs and healthy tissue for RapidArcTM with the same
target coverage.
A recent dosimetric comparison of RapidArcTM and helical tomotherapy between two in-
stitutions in the US for four different cancer sites - brain, head-and-neck, lung and prostate
- arrived at the same conclusion: the treatment time and number of MUs is reduced with
RapidArcTM , while the target dose uniformity and coverage is better with helical to-
motherapy. Moreover, helical tomotherapy provided a slightly better dose sparing of most
OARs [46].
RapidArcTM dose delivery is just beginning to be used in the clinic, and therefore no
outcome data from treated patients is available yet. All comparisons between single arc
therapy and other intensity-modulated treatment techniques are based on treatment plan
comparisons. The comparison of helical tomotherapy and RapidArcTM , two competing
technologies manufactured by different commercial vendors, led to a controversy on the
advantages and disadvantages of both dose delivery techniques. Triggered by statements
made in a paper on the commissioning and quality assurance of RapidArcTM [28], there
was a discussion of beam-on-times and the impact of MLC leaf width and slice thickness on
the dose conformity for RapidArcTM and helical tomotherapy ([30], [33], [27]). It should
be noted that all statements concerning the quality of dose distributions or the perfor-
mance of any dose delivery technique naturally depend on the current implementation of
the techniques. Delivery parameters such as leaf width, pitch etc. used for the treatment
plan comparisons in this chapter were chosen to be consistent with typical clinical settings.
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The influence of several delivery parameters on the final dose distribution obtained with
AMCBT is further examined in chapter 5.
4.1 Comparison of IMRT and AMCBT
The three selected clinical cases are typical indications for a treatment with intensity mod-
ulated fluence fields - a radiation sensitive organ is enclosed by a concave shaped target.
For all calculations the bixel resolution was set to (5 mm)2, the voxel size to (2.62 mm)3
and the photon beam energy was 6 MV. The optimization process for AMCBT was per-
formed with Nk = 36 beam directions. As an initial solution, the bixel sets A
2++
k were
taken (see 3.1.2) with a minimum field size of Nc = 5 bixels. The length of the tabu list
was set to t = 100, but actually no tabu event occured. A re-calculation of the beam
weights was performed once in every iteration step (p = 1, q = 1). The dose constraints
were the same for the IMRT and the AMCBT optimization processes.
4.1.1 Prostate carcinoma
The first example considered is a prostate carcinoma which is shown in figure 4.1. The dose
was delivered in 38 fractions of 2 Gy. For the gross tumor volume (GTV) the maximum
and minimum dose constraint was 76 Gy. The GTV is surrounded by the clinical target
volume (CTV) with a margin of 5 mm without overlapping any OARs and the planning
target volume (PTV) with a margin of 5 mm to the CTV with possible overlap of OARs.
The maximum and minimum dose constraints for these two volumes was 66 Gy.
(a) IMRT (b) AMCBT
Figure 4.1: Comparison of the dose distributions in a transversal slice for IMRT and
AMCBT for the prostate case. A dose of 100% in the dose scale equals 76 Gy. The
rectum is contoured in green, the PTV in pink and the GTV in red.
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The following OARs were considered during the optimization loop: the rectum with a
dose limit of 45 Gy, the bladder with a dose limit of 30 Gy and the femurs with a dose
limit of 30 Gy. For the IMRT optimization, dose volume constraints were used to achieve
a better sparing of the rectum and the normal tissue was included in the optimization
with a maximum dose of 20 Gy.
For the IMRT treatment plan seven equidistant beam directions were selected. The num-
ber of intensity levels for the subsequent stratification of the fluence maps was four, which
resulted in 43 IMRT segments to be delivered.
A comparison of the dose distributions for the AMCBT and IMRT treatment plans is
shown in the dose volume histogram (DVH) in figure 4.2. The curves are normalized so
that 50% of the GTV receive at least 100% of the prescribed dose.
In the GTV the maximal dose is lower for AMCBT (solid line) and the minimal dose is
higher, which results in a more homogeneous dose distribution in the target volume.
In the rectum the mean dose is much lower for AMCBT than for IMRT, i.e., DIMRT =
35.8% of the prescribed dose and DAMCBT = 27.2%. However, in the high dose region
of the rectum the dose distribution is slightly better for IMRT, although the respective
maximal dose is higher for IMRT, i.e., DmaxIMRT = 102.1% compared to D
max
AMCBT = 100.1%.
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Figure 4.2: Comparison of the DVH curves for IMRT (dashed) and AMCBT (solid) for
the prostate case.
Figure 4.1 displays the dose distributions on a transversal CT-slice. The conformation
of the dose distribution to the target volume and the sparing of the rectum is visible for
both treatment plans. AMCBT is especially good in the region of the rectum not directly
adjacent to the target.
Another notable difference between the treatment plans for AMCBT and IMRT is the
number of MUs to be delivered. For the IMRT treatment the total number of MUs was
1100 MUs in comparison to 639 MUs for AMCBT.
30 4 Treatment plan comparisons
case 1 case 2 case 3
IMRT AMCBT IMRT AMCBT IMRT AMCBT
GTV min 85.9 87.9 56.4 71.8 76.7 78.4
GTV max 115.7 109.4 115 110.6 115.7 106
Rectum mean 35.8 27.2 53.4 36.1 45.5 28.7
Rectum max 102.1 100 98.2 98.1 92.4 96.9
MUs 1100 639 1202 580 1190 549
Table 4.1: Dose values (in % of the prescribed dose for the GTV) and number of monitor
units (MUs) for three different prostate carcinomas. The dose distribution on a transversal
slice for case 1 is shown in figure 4.1
Calculations for other prostate carcinomas showed similar results: a reduction of the num-
ber of MUs, a similar dose distribution in the target, which was mostly slightly better for
AMCBT, and a much lower mean dose in the rectum for AMCBT accompanied by a
somewhat better sparing in the high dose region (see table 4.1).
4.1.2 Paraspinal tumor
The second example considered is a paraspinal tumor. In this case the spinal cord is en-
closed by the tumor volume, as shown in figure 4.4. Therefore, the spinal cord was chosen
as the most important OAR for the generation of the initial field shapes. For the tumor
the maximum and minimum dose constraint was 60 Gy. A maximum dose constraint of
35 Gy was set for the spinal cord, the kidney and the intestine. The normal tissue was
only considered for the IMRT treatment plan with a constraint of 20 Gy.
For the IMRT treatment, five equidistant coplanar beam directions were chosen and the
number of intensity levels was six which results in 51 IMRT segments for this treatment.
To optimize the AMCBT treatment plan 1000 iterations were performed. The resulting
DVHs and the transversal views for this example are shown in figures 4.3 and 4.4.
Figure 4.3: Comparison of the
DVH curves for IMRT (dashed)
and AMCBT (solid) for the
paraspinal case. Displayed are
the target (red) and spinal cord
(green).
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The dose distribution in the target volume is very similar for IMRT and AMCBT. The
mean dose in the most important OAR, the spinal cord, is D
spinalcord
IMRT = 21.7% of the
prescribed dose for the IMRT treatment plan and D
spinalcord
AMCBT = 18.8% for AMCBT.
But for this case the maximal dose is higher for AMCBT (Dspinalcord,maxIMRT = 85.7%,
Dspinalcord,maxAMCBT = 95.2%). The difference in the number of MUs is not as pronounced
as for the prostate cases, but nevertheless the number of MUs could be reduced from 592
MUs for IMRT to 512 MUs for AMCBT.
(a) IMRT (b) AMCBT
Figure 4.4: Comparison of the dose distributions in a transversal slice for IMRT and
AMCBT for the paraspinal case. A dose of 100% in the dose scale equals 60 Gy. The fol-
lowing VOIs are shown in this slice: Target (pink), spinal cord (purple), intestine (green)
and kidney (yellow).
4.1.3 Head tumor
The geometry of the anatomical structures for this clinical case is more complicated than
the two cases considered before. The irregularly shaped target is in close proximity to the
optical nerves and other organs at risk such as brainstem, spinal cord and optical chiasm
that all have to be spared from unacceptable dose burden. This geometry is not appropri-
ate for the generation of initial field shapes, as explained in section 3.1.2, due to the high
number of sensitive structures. Instead, the optimization started with target conformal
field shapes.
The clinical IMRT plan was calculated with 7 beam directions and a bixel size of 2.75 mm.
The voxel size was 1.6 mm. To generate the treatment plan for AMCBT the number of
beam directions was 36 and the same bixel and voxel size as for the IMRT plan were used.
The number of optimization steps was increased to 5000 due to the higher complexity of
this case. Moreover, the declaration of the neighbourhood was changed for the first 2000
iteration steps. Instead of changing the field shapes by opening or closing 1 bixel, the
neighbourhood was calculated for field changes of 3 bixels.
A comparison of the DVHs for the IMRT and AMCBT treatment plans is shown in figure
4.6. Besides the target volume the DVH is shown for the right and left optical nerve,
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the right and left eyes, the brainstem, the spinal cord and the optical chiasm. For this
patient the dose coverage of the target volume and the dose conformity is better for IMRT.
The sparing of the OARs is similar for both treatment techniques. Some OARs receive
less dose with the IMRT treatment plan, e.g. a mean dose of 18.4 Gy in the brain stem
compared to 21.6 Gy for AMCBT. Other OARs are better spared with AMCBT, e.g. the
left optical nerve and eye and also the chiasm. The dose to the normal tissue is higher for
AMCBT. The possibility of a very conformal dose distribution with both delivery methods
is demonstrated in the transversal slices in figure 4.5.
(a) AMCBT
(b) IMRT
Figure 4.5: Comparison of the dose distributions in a transversal slice for AMCBT and
IMRT. The target is contoured in pink, the eyes in orange, the optical chiasm in turquoise
and the optical nerves in blue.
The left side of the figure shows a CT-slice where the target is close to the optical nerves
and the eyes. A sparing of the OARs and a good coverage of the target is visible for both
treatment plans. The other CT-slice display shows a higher dose to the normal tissue for
the AMCBT treatment plan.
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Figure 4.6: Comparison of the DVH curves for IMRT (dashed) and AMCBT (solid).
Displayed are the target (red), the optical nerves (blue), the eyes (orange), the optical
chiasm (pink), the brainstem (turquoise) and the spinal cord (green).
The required number of MUs for a prescribed dose of 60 Gy that is to be delivered in 30
fractions is 231 MUs per fraction for AMCBT and 1026 MUs for IMRT.
4.2 Comparison of tomotherapy and AMCBT
Tomotherapy can produce distributions with a good target coverage and homogeneity to-
gether with individualized sparing of organs at risk (OARs) in a variety of tumors [[56],
[55], [43], [44], [12]]. Several planning studies for the treatment of head-and-neck cancer
showed that helical tomotherapy can realize sharper dose gradients and a better sparing
of parotid glands compared with step-and-shoot IMRT or stereotactic radiotherapy [[67],
[15], [52], [49]]. In addition, new treatment possibilities were realized by the means of
tomotherapy, for example the delivery of whole abdominal irradiation [45].
In the present study three different types of cancer with varying position, geometry and
boost concepts were used to compare the two planning methods in different clinical set-
tings. The rationale for IMRT of anal cancer is the sparing of the genitals, bladder and
small bowel and, consequently, an improvement of the efficacy-toxicity ratio [31]. Com-
bined radiochemotherapy is the standard treatment of anal carcinoma and has proven
to be highly effective in sphincter preservation [[18], [36]]. However, radiation associated
toxicity can cause treatment interruptions and thereby diminish the tumor control proba-
bility [14]. Low genitourinary and gastrointestinal toxicity rates were reported when using
IMRT by several groups [[47], [32]].
The motivation of using IMRT in head-and-neck cancer has been outlined in numerous ar-
ticles and reviews and is mainly based upon the need for dose reduction to parotid glands,
spinal cord, esophagus and larynx [20]. Besides the improvement of local control IMRT
has a huge impact upon quality of life by reducing long term toxicity as xerostomia and
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dysphagia [54].
Similar to the background of the two previously described tumor types the main motiva-
tion for the use of IMRT in the management of prostate cancer is to enable a safe dose
escalation while sparing the rectum and thereby reducing gastrointestinal toxicity [76].
The aim of this study is the evaluation of single arc therapy in comparison to helical
tomotherapy.
4.2.1 Patient selection
To cover a wide variety of different geometries with different complexity and different ob-
jectives we compared treatment plans for tomotherapy and single arc therapy for three
different tumor sites. The total number of patients was nine, all of which had been previ-
ously treated with helical tomotherapy.
Prostate carcinoma:
Three patients with histologically proven intermediate risk localized prostate cancer were
chosen for this planning comparison.
Patient 1: T2cN0M0, Gleason score 7(4+3), PSA-level 5.3 ng/ml
Patient 2: T1cN0M0, Gleason score 6(3+3), PSA-level 18 ng/ml
Patient 3: T1cN0M0, Gleason score 7(4+3), PSA-level 4.9 ng/ml
A dose of 76 Gy was prescribed to 95% of the volume of the prostate itself. This vol-
ume was extended by 6 mm and modified to include the seminal vesicles and exclude the
rectum. A median dose of 70 Gy was prescribed to this volume. In a third step this
volume again was extended by 6 mm and a median dose of 66 Gy was prescribed. The
treatment was performed in 35 fractions. The organs at risk included the bladder, rectum
and femoral heads. For the OARs no specified dose limits were used, instead the dose was
minimized as much as possible.
Anal carcinoma:
Three patients with histologically confirmed anal cancer that had previously undergone
combined radiochemotherapy were chosen for the study. The patients‘ characteristic were
as follows:
Patient 1: T2N2M0
Patient 2: T3N1M0
Patient 3: T2N1M1 (single bone metastasis)
The CTV included the tumor region plus the draining lymphatics in the perirectal, inter-
nal and external iliac and inguinal region. A safety margin of 5 mm was added to create
the PTV to account for setup uncertainties. A median dose of 45 Gy was prescribed in 25
fractions. The organs at risk were genitals, bladder and small bowel.
Oropharynx carcinoma:
Three patients with squamous cell carcinoma of the oropharynx with a postoperative sta-
tus were chosen.
Patient 1: pT3pN1M0, with extracapsular tumor extension and positive resection margins
Patient 2: pT3cN2M0, the patient had refused lymph node dissection, only marginal tu-
mor resection was performed
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Patient 3: pT2mpN2cM0L1, with positive resection margins
The boost region was defined as the preoperative tumor region detected on contrast en-
hanced CT and MRI scans plus a 5 mm margin. The CTV encompasses the draining
lymphatics. A median dose of 70.4 Gy in 32 fractions was prescribed to the primary
tumor region and to the involved lymph nodes within a simultaneous integrated boost
concept. A median dose of 57.4 Gy in 32 fractions was prescribed to the cervical and
supraclavicular lymphatics. Organs at risk were spinal cord, brain stem, parotis, larynx,
esophageal sphincter and lungs.
4.2.2 Treatment planning
Tomotherapy
Helical tomotherapy planning was done with the Hi-Art Tomotherapy planning system
version 2.2.1.55 (Madison, Wisconsin, USA). Contouring was performed with the Oncol-
ogist software by Siemens. The dose delivery was accomplished with a longitudinal field
width of 2.5 cm and a pitch of 0.287 with 6 MV x-rays.
Arc-modulated cone beam therapy
Single arc treatment plans were optimized with the algorithm described in section 3. For
dose delivery of rotational treatment plans the following constraints of the dose delivery
hardware were considered. The gantry rotates with a constant speed ranging between
50 ◦/min and 360 ◦/min. The speed of the rotation is determined by the total number of
MUs required for the treatment. During the rotation the dose rate can be varied between
30 MU/min and 300 MU/min. The maximum speed of the MLC leaves is restricted to
3 cm/s.
All treatment plans were optimized with a voxel size of (2.62mm)3, a bixel size of (5mm)2
and a beam energy of 6 MeV. The number of beam directions used during the optimization
was 51 for the prostate and head and neck cases, which is the same number as used for
tomotherapy planning. Due to limited memory of our optimization hardware the number
of beam directions for the optimization of the anal carcinoma cases was limited to 36.
In a post-optimization step the number of beam directions was increased from 51 or 36
beams to 360 beams by linear interpolation of the determined MLC positions and MUs.
The final dose distributions for these treatment plans were then calculated with a clinically
approved pencil beam algorithm.
Treatment plan comparison
Treatment plans, structure sets and CT data were imported in Dicom format from the HT
planning system to the treatment planning system VIRTUOS. Consequently, the AMCBT
optimization process could be based on the same CT data and the same VOIs that were
used for tomotherapy. The evaluation of the treatment plans was done by the same
physician for AMCBT and helical tomotherapy.
For plan comparison we used dose-volume based parameters. For OARs the mean dose and
D1% are calculated. For the target we compared D1%, D99%, mean dose, dose coverage, e.g.
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the ratio of the target volume receiving 95% of the prescribed dose and the total target
volume, and conformity, e.g. the ratio of target volume receiving 95% of the dose and the
total volume receiving 95% of the dose. Moreover, the integral dose was calculated as the
product of the mean dose delivered to the volume bounded by the patient body contour.
4.2.3 Results
Prostate carcinoma
In table 4.2 the mean dose values for the three patients involved in this study are listed.
The mean dose-volume histogram is shown in figure 4.8, and examples of the dose distri-
butions for helical tomotherapy and arc-therapy in a transversal and a sagittal slice for
one patient are displayed in figure 4.7.
(a) AMCBT
(b) Tomotherapy
Figure 4.7: Dose distribution for prostate patient 1. The left column shows a transversal
slice, the right column a sagittal slice. The 100% isodose line refers to 78 Gy.
With single arc therapy a very good dose sparing of the rectum is possible. Also the mean
dose to the bladder is lower for arc therapy. The conformity of the dose to the target is
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organ Tomo AMCBT
GTV
D99% 72.8 73.2
D1% 80.4 81.9
mean 78.0 78.0
CTV
D99% 68.0 66.3
D1% 80.1 81.5
mean 74.9 75.3
PTV
D99% 59.6 58.3
D1% 79.8 81.7
mean 71.4 72.2
coverage 0.68 0.75
conformity 1.00 0.99
Rectum
D1% 67.5 72.1
mean 24.4 21.7
Bladder
D1% 72.8 75.1
mean 25.2 23.6
Integral dose 172.0 145.8
Table 4.2: Mean dose values for tomotherapy (Tomo) and AMCBT for three patients
with prostate cancer (dose values in Gy, integral dose in Gyl).
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Figure 4.8: Mean dose volume histogram for the three prostate cancer patients. The solid
lines represent the arc therapy plan, the dashed lines refer to the tomotherapy plan.
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slightly enhanced for tomotherapy, whereas arc-therapy yields better results for the dose
coverage. A comparison of the mean dose in the patient contour shows lower values for
arc therapy. The integral dose, i.e. the sum of the dose values in all voxels, is 15% lower
for AMCBT compared to tomotherapy.
The dose distribution in the sagittal slices shows a very steep dose gradient in the longi-
tudinal direction for arc therapy, whereas for tomotherapy there is a relatively high dose
in the normal tissue above and below the tumor. This phenomenon is caused by the
helical delivery of tomotherapy. For arc therapy, the projection of the target determines
the maximum size of the fluence field, and therefore the dose above and below the target
decreases very rapidly. In helical tomotherapy the leaves of the binary MLC start to open
as soon as the top of the target is in the field of view of the radiation source. Therefore
a higher dose is also delivered to the normal tissue that is within the range of the MLC
field width to the target.
The delivery time for tomotherapy was 382s, 368s and 285s for patient 1, 2 and 3, respec-
tively, with an average of 5.75 minutes. Since arc therapy was not performed, only an
estimation of the treatment time is possible. This estimation depends on the hardware
limitations, e.g. the gantry rotation speed, the velocity of the MLC leaves and the dose
rate. For a maximum dose rate of 300 MU/min and a MLC leave velocity of 3 cm/s,
we estimate a treatment time between 2 and 3 minutes for single rotation therapy. With
higher dose rates the treatment time could be further reduced.
Anal carcinoma
The group of patients with anal cancer is characterized as having very large target volumes
(mean PTV volume = 1905 cm3) and a high degree of concavity. Several transversal slices
shown in figure 4.9 point out the high geometrical complexity for this class of cases.
In table 4.3 the averaged dosimetric parameters are listed for the three patients. For this
patient group the dose distribution in the target is better for tomotherapy. The dose cov-
erage of the PTV is higher for tomotherapy and also the conformity is slightly improved.
In bladder and bowel the dose distributions of AMCBT and tomotherapy lead to similar
mean doses. The mean dose to the genitals is slightly lower for tomotherapy, in the high
dose region AMCBT delivers less dose. The mean dose to the patient contour is again
lower for arc therapy.
The dose-volume histogram for patient 1 (figure 4.10) points out the better dose distri-
bution in the PTV for tomotherapy. The dose distribution in figure 4.9 shows a good
conformity to the tumor for both techniques. Even the separation of the target volume
in several parts is very well possible with single arc therapy. The larger volume of the
PTV compared to the prostate cases naturally leads to a longer treatment time for to-
motherapy, on average the dose delivery takes 10 minutes. In arc-modulated cone beam
therapy the treatment time depends on the rotation speed of the gantry. For the dose
rate and MLC limitations stated previously the gantry rotation speed for these case will
be approximately 140 ◦/min resulting in a treatment time of 2.5 minutes.
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(a) Arc-modulated cone beam therapy
(b) Tomotherapy
Figure 4.9: Dose distribution in 3 transversal slices for patient 1 with anal cancer. The
isodose line with 100% dose corresponds to 45 Gy. Displayed are the target (red), bladder
(green) and genitals (blue).
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organ Tomo AMCBT
PTV
D99% 39.6 35.7
D1% 47.5 50.3
mean 45.0 45.0
coverage 0.97 0.82
conformity 0.88 0.86
Genitals
D1% 45.6 42.1
mean 17.5 19.5
Bowel
D1% 40.2 43.2
mean 6.7 6.7
Bladder
D1% 46.7 44.9
mean 28.0 29.3
Integral dose 316.7 290.8
Table 4.3: Mean dose values for tomotherapy (Tomo) and AMCBT for three patients
with anal cancer (dose values in Gy, integral dose in Gyl).
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50
volume [%]
dose [Gy]
PTV
genitals
bladder
bowel
Figure 4.10: Mean dose volume histogram for three patients with anal carcinoma. The
solid lines represent the treatment plan for AMCBT, the dashed lines refer to the tomother-
apy plan.
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Oropharynx carcinoma
For this group of patients with a tumor in the head and neck region two different dose
levels were prescribed, 57.6 Gy in the PTV and 70.4 Gy in the boost region(s). The pa-
rameters derived from the dose-volume information are summarized in table 4.4. In the
PTV the dose coverage and conformity are improved for tomotherapy. Also in the boost
region the variation of the dose is higher for AMCBT. The dose sparing for most OARs is
better possible with tomotherapy, especially the dose to the parotids, which are very close
to a boost volume, is lower with this technique. With arc-therapy a very good sparing of
the brain stem was possible. As seen for the other cases as well, the integral dose is lower
for arc therapy compared to tomotherapy, for this patient group by 10%.
(a) Arc-modulated cone beam therapy
(b) Tomotherapy
Figure 4.11: Dose distribution for patient 1 with oropharynx cancer. The upper row
represents arc-therapy, the lower row tomotherapy. The 100% isodose line equals 70.4 Gy.
Displayed are the target (red), parotid glands (green), brain stem (light blue) and spinal
cord (blue).
The DVH (figure 4.12) shows the better coverage of the PTV for tomotherapy, and also
the lower dose to most OARs. In the transversal slice of the dose distribution (figure
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organ Tomo AMCBT
Boost
D99% 65.4 60.7
D1% 71.0 73.7
mean 68.9 68.3
PTV
D99% 49.4 43.8
D1% 69.9 71.6
mean 57.6 57.6
coverage 0.81 0.69
conformity 0.94 0.88
Parotid glands
D1% 54.2 51.0
mean 20.1 28.5
Brain stem
D1% 24.7 29.5
mean 9.2 7.4
Spinal cord
D1% 21.2 29.0
mean 12.0 14.5
Larynx
D1% 59.1 61.4
mean 40.5 48.9
Trachea-esophagus
D1% 47.4 52.0
mean 27.2 34.4
Integral dose 206.1 183.8
Table 4.4: Mean dose values for tomotherapy (Tomo) and AMCBT for three patients
with oropharynx cancer (dose values in Gy, integral dose in Gyl).
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Figure 4.12: Mean dose volume histogram for three patients with oropharynx cancer.
The solid lines represent the treatment plan for AMCBT, the dashed lines refer to the
tomotherapy plan.
4.11) the position of the boost volume is shown and its close proximity to the parotid
gland. With tomotherapy planning it was possible to spare this OAR very well from dose,
but also with arc therapy a steep dose gradient between the boost volume and the left
parotid gland is achievable. The sagittal view shows a better dose sparing of the neck
with tomotherapy, but with tomotherapy the fall-off of the dose in longitudinal direction
is not as steep as for arc-therapy.
4.3 Comparison of AMCBT and ”idealized IMRT”
The comparison of AMCBT and helical tomotherapy in section 4.2 showed better dose
shaping capabilities for helical tomotherapy for complex patient geometries. In this section
it is examined how much the dose distributions for single arc therapy could be improved by
adding additional arcs. Therefore, treatment plans with modulated fluence fields and the
same number of beam directions as for AMCBT were created. The final dose distribution
was calculated for the optimized fluence maps and no stratification and sequencing was
performed. The dose delivery of such a treatment plan would take very long, but with an
appropriate sequencing algorithm it would be possible to convert the modulated fluence
fields in a set of deliverable aperture shapes. Therefore the dose distributions shown in
this section represent the optimal solution for the respective dose constraints.
In the following section the treatment plans with a high number of beam directions and
intensity-modulated fluence fields are referred to as ”idealized IMRT” treatment plans.
The dose constraints and penalty factors used for the optimization were the same as for
AMCBT treatment plans. It should be noted that a comparison of ”idealized IMRT” and
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helical tomotherapy is not intended, since the dose constraints were chosen to find the
best AMCBT treatment plan instead of the ”idealized IMRT” treatment plan.
Prostate cancer
For the group of patients with a prostate carcinoma the differences in the dose distribution
between AMCBT and helical tomotherapy were small. Table 4.13 displays the dose values
for AMCBT and ”idealized IMRT” for one example case. The corresponding dose volume
histogram for AMCBT and ”IMRT” is shown in figure 4.14. Differences in the dose
distributions for the three different techniques are small. The higher dose in the rectum
in the low dose region for ”IMRT” is due to the dose constraint used for this OAR, which
only penalizes dose values above 42 Gy. Besides the higher dose to the rectum, the dose
values listed in table 4.13 are very similar for AMCBT and ”IMRT”. This indicates that
a dose delivery in several rotations would not improve the quality of the dose distribution
that is achievable within a single rotation.
organ AMCBT ”IMRT”
GTV
D99% 74.2 76.0
D1% 81.4 80.0
mean 78.0 78.0
CTV
D99% 67.7 68.4
D1% 80.9 81.6
mean 75.2 75.3
PTV
D99% 60.3 60.4
D1% 80.5 80.6
mean 72.3 72.4
Rectum
D1% 70.1 72.4
mean 21.1 23.6
Bladder
D1% 74.4 74.1
mean 26.3 26.2
Contour
D1% 50.4 50.1
mean 4.7 4.7
Figure 4.13: Dose values for AM-
CBT and ”ideal IMRT” for a pa-
tient with prostate cancer (values in
Gy).
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80
volume [%]
dose [Gy]
Figure 4.14: Dose volume histogram for a
patient with prostate cancer. The solid line
represents the dose distribution for AMCBT,
the dashed line for ”idealized IMRT”.
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Oropharynx cancer
The comparison of AMCBT and helical tomotherapy for oropharynx cancer patients
showed a better dose distribution for helical tomotherapy. Table 4.5 summarizes the
dose values for one example case for AMCBT, tomotherapy and ”idealized IMRT”. For
the complex geometry present for oropharynx cancer it was possible to improve the dose
distribution with intensity modulated fields compared to AMCBT. The dose to all OARs
was reduced, in the target volume the dose coverage and conformity were improved. The
integral dose for this treatment plan is not higher compared to the AMCBT treatment
plan (203 Gyl for AMCBT, 204 Gyl for IMRT, 250 Gyl for tomotherapy).
organ Tomo AMCBT ”IMRT”
PTV
D99% 49.0 45.5 50.8
D1% 71.6 69.7 70.9
mean 57.6 57.6 57.6
Boost
D99% 67.6 63.1 66.2
D1% 72.8 71.7 73.7
Parotid glands
D1% 53.0 52.7 50.3
mean 22.3 29.9 22.3
Brain stem
D1% 20.9 28.7 17.8
mean 6.6 6.0 5.3
Spinal cord
D1% 22.6 30.8 21.7
mean 12.3 15.5 12.9
Larynx
D1% 58.4 58.2 58.9
mean 29.3 38.8 31.9
Trachea-esophagus
D1% 39.7 43.7 37.5
mean 24.6 28.9 20.4
Lung
D1% 42.9 54.6 45.9
mean 7.5 7.0 6.2
Contour
D1% 59.8 62.7 60.4
mean 15.6 12.6 12.7
Table 4.5: Dose values for helical tomotherapy, AMCBT and ”ideal IMRT” for a patient
with oropharynx cancer (values in Gy).
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For this patient a dose delivery in more than a single rotation would lead to an improved
quality of the dose distribution. The question of how many arcs are needed to achieve the
same quality as possible with helical tomotherapy is not answered with the comparison
performed in this section. Another open issue is the treatment time needed for a dose
delivery in several rotations.
(a) Constant fluence - AMCBT
(b) Modulated fluence - IMRT
Figure 4.15: Comparison of the fluence distributions for intensity-modulated fields and
AMCBT.
Figure 4.15 shows examples of the fluence maps for AMCBT and IMRT for a few beam
directions. The fluence maps are displayed for gantry angles of 194◦, 201◦, 208◦ and 215◦.
The different gray values symbolize a different number of MUs per field or bixel. For
AMCBT the fluence within each field is constant, but the number of MUs varies between
beam directions. For IMRT the field shape conforms to the beam´s eye view of the target
and within the field the fluence is modulated. The fluence maps for IMRT clearly show
the much lower intensity in areas where the beam hits an OAR.
5 Stability of AMCBT treatment plan
quality
The quality of treatment plans for radiotherapy is influenced by many factors. The sta-
bility of the treatment plan quality is investigated for several aspects that have an impact
on the final dose distribution achievable with AMCBT. First, the influence of hardware
limitations is examined in section (5.1). The next section (5.2) deals with the influence
of different primary fluence profiles on the final dose distribution. For a variety of pa-
rameters, e.g. the MLC leaf width, the number of beam directions used for treatment
planning or the collimator angle, the effect on the treatment plan is investigated (section
5.3). In the last section of this chapter the stability of the dose distribution for imposed
dose delivery errors is examined (section 5.4).
5.1 Hardware limitations
To account for the limitations imposed by the dose delivery hardware the following con-
straints were included into the optimization: a minimum and maximum beam weight
(depending on the dose rate of the linac), a maximum change of consecutive beam weights
(depending on the achievable variation of the dose rate) and a maximum change of consec-
utive aperture shapes (depending on the speed of the MLC leaves). All these limitations
depend on the gantry rotation speed, which is calculated based on the total number of
MUs to be delivered and is assumed to be constant for one treatment. A detailed descrip-
tion how the constraints were included into the optimization concept was given in section
3.2.
For a Siemens ArtisteTM linac equipped with a 160MLCTM gantry speeds between 50◦/min
and 360◦/min are possible and the dose rate can vary between 30MU/min and 300MU/min
with a maximum variation rate of 20 MU/min per second. The maximum physically
achievable leaf speed of the 160MLCTM is 4 cm/s, but during the optimization it was set
to 3 cm/s. The restriction of the leaf speed to a value that is lower than the maximum
speed offers the possibility to perform arc therapy together with tumor tracking.
In this section, treatment plans for AMCBT which were optimized with or without con-
sidering limitations imposed by the hardware are compared. To further examine the
influence of the different hardware limitations on the quality of the dose distribution,
treatment plans for which only a part of the limitations are considered were calculated.
This was done for a total of four different tumor types. The treatment plan generated
with an unconstrained optimization was defined as the optimal dose distribution for the
respective case.
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Results
The first case under investigation is a prostate cancer patient. Treatment planning was
performed for 36 fixed beam directions. During the optimization loop the ”optimal” gantry
rotation speed was determined to be 120 ◦/min. If the hardware limitations are not con-
sidered in the optimization, the dose rate varies between 0 MU/min and 624 MU/min.
Figure 5.1 shows the influence of the dose rate limitation on the number of MUs per beam
direction. For the given gantry rotation speed and a dose rate between 30 MU/min and
300 MU/min, the number of MUs per beam is limited between 2.5 MU and 25 MU , as
visible for the green curve in figure 5.1. The red curve shows the number of MUs per
beam for the treatment plan in which the maximum variation of the dose rate was also
considered. Differences of the three curves are only visible for very low or high dose rates,
for all other angles the number of MUs is very similar for the three different optimization
runs.
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Figure 5.1: Number of monitor units per aperture for treatment plans optimized without
considering hardware limitations (blue), considering a minimum and maximum dose rate
(green) and considering also a maximum variation of the dose rate (red).
With a gantry rotation speed of 120 ◦/min the maximum distance the MLC leaves can
move in a 10◦ interval is 15 cm. Figure 5.2 shows an example of the movement of three leaf
pairs for a treatment plan that was generated without considering the limitations imposed
by the hardware and a plan in which all hardware limitations were included. All leaf
movements clearly stay within the limit of 15 cm. Small differences in the leaf movements
between the treatment plans are presumably caused by the different beam weightings im-
posed by the dose rate limitations. Figure 5.2 shows the leaf pairs 44, 45 and 46 from a
total of 80 leaf pairs, these leaf pairs are situated in the middle of the open field. None of
the leaves exceeded the maximum movement of 15 cm, therefore limitations imposed by
the MLC do not alter this treatment plan.
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(b) with consideration of hardware constraints during optimization
Figure 5.2: Example for the movement of three leaf pairs for the prostate cancer treatment
plan. The movement of the right leaf is displayed in green, for the left leaf in red.
The dose distributions calculated for treatment plans that were optimized with and with-
out considering hardware constraints during the optimization show almost no differences
for this patient (see figure 5.4).
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Figure 5.3: Dose volume histogram for
treatment plans that were optimized with-
out (solid line) and with (dashed line) con-
sideration of limitations imposed by the
dose delivery hardware.
For the second example under investigation - a meningioma - there are bigger differences
in the number of MUs per beam direction (see figure 5.5). For this case the total number
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(a) without constraints (b) with constraints
Figure 5.4: Influence of hardware constraints on the dose distribution for a prostate
cancer case. Displayed are the PTV (pink), CTV (red), PTV (red) and rectum (green).
of monitor units is lower and therefore a faster rotation speed was calculated for dose
delivery. For a gantry rotation speed of 214 ◦/min the number of MUs per 10◦ interval
is limited between 1.4 MUs and 14 MUs. Without considering this limitation in the
optimization the maximum number would exceed 28 MUs per beam, which corresponds
to a dose rate of 600 MU/min.
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Figure 5.5: Influence of hardware limitations on the number of monitor units for a menin-
gioma cancer patient. The blue curve represents a treatment plan that was optimized with-
out constraints in the optimization, the red curve a treatment plan for which all hardware
limitations were considered in the optimization.
For this example case the limitations imposed by the hardware lead to differences in the
dose distribution. In the transversal slice of the dose distribution displayed in figure 5.7 the
better sparing of the eyes and optical nerves for an unconstrained optimization is visible.
Also the dose to other OARs is increased and the dose coverage of the target is decreased
for the treatment plan that considers the dose rate limitations (see DVH in figure 5.6).
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Figure 5.6: Dose volume histogram for a meningioma patient. The solid lines represent
a treatment plan that was optimized without consideration of hardware limitations during
the optimization, the dashed lines represent a treatment plan generated with consideration
of limitations imposed by the hardware.
Even though the gantry rotation speed is faster for this example case, the inclusion of
MLC limitations in the optimization did not lead to an increase in the final objective
function value or differences in the dose distribution.
An investigation of the influence of hardware constraints on the objective function value
for two more cases (head, pancreas) also showed increasing values for an optimization with
hardware constraints. In table 5.1 the objective function values for the four cases for all
optimization runs are summarized. All values were normalized to the objective function
value for an optimization without hardware constraints.
prostate meningioma head pancreas
without constraints 1.00 1.00 1.00 1.00
with all constraints 1.01 1.43 1.22 1.19
only MLC constraints 1.00 1.01 1.13 1.01
only DR constraints 1.01 1.22 1.05 1.18
only min/max DR 1.00 1.11 1.05 1.14
Table 5.1: Objective function for optimization runs with different hardware limitations
In the current implementation of the optimization algorithm the gantry rotation speed is
determined at the beginning of the optimization based on the expected number of MUs.
For the meningioma case shown above, the influence of different gantry rotation speeds
on the plan quality was examined. Both a faster and a slower rotation speed led to an
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(a) without constraints (b) with constraints
Figure 5.7: Dose distribution for a meningioma treatment plan optimized with and with-
out hardware constraints. Displayed are the PTV in pink, the eyes in purple, the optical
nerves in orange and red and the brainstem in green.
increase of the objective function value compared to the optimization run with 214 ◦/min.
With a rotation speed of 180 ◦/min or 280 ◦/min the final value of the objective function
increases by approximately 10%.
5.2 Beam flattening filter
The basic idea of a beam flattening filter was explained in section 2.2. The advantage of
a laterally flattened beam profile is an almost constant intensity throughout the radiation
field. For conformal treatment techniques this results in a more homogenous dose distri-
bution within the tumor. However, in IMRT there is the possibility to increase the weight
of bixels at the edge of the radiation field and therefore a homogeneous dose distribution is
also possible without flattening the beam profile. In this section the influence of different
primary fluences on the quality of dose distributions for rotation therapy was examined.
The advantage of removing the flattening filter is a higher dose rate and therefore poten-
tially a shorter treatment time.
Beam profiles with and without the flattening filter were measured with a Siemens accel-
erator. Figure 5.8 shows the profiles for both situations for a 6 MV beam. Both curves
were normalized to 1 at the center of field. The figure shows a much steeper off-axis dose
decrease for the non-flattened beam. By removing the beam flattening filter the maximum
dose rate of 300 MU/min could be increased to 1000 MU/min.
To investigate the treatment plan quality achievable with an unflattened beam profile
treatment plans for both primary fluences were calculated. Hardware constraints, e.g. the
MLC leaf speed or the dose rate limits, were not considered in the optimization. The same
planning constraints and optimization concept were used for the optimization of treatment
plans for both primary fluences.
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Figure 5.8: Normalized primary fluences
with (solid line) and without (dashed line)
a flattening filter in the beam.
Treatment plans were generated for three cancer types with different target sizes and ge-
ometries. The prostate cancer case had a relatively small target volume of 262 cm3 which
was prescribed a dose of 78 Gy in 35 fractions. For the anal cancer case the target struc-
ture was concave in shape with a volume of 1917 cm3 and the genitals and bladder were
in close proximity. The prescribed dose was 45 Gy in 25 fractions. The most complex
geometry is represented by an oropharynx cancer case with two boost volumes within the
PTV with dose levels of 56.4 Gy and 70.4 Gy for a dose delivery in 32 fractions.
Results
The final value of the objective function was approximately 10% worse if the flattening
filter was not in the beam. Also increased is the total number of monitor units by 11%,
35% and 42% for prostate cancer, anal cancer and oropharynx cancer, respectively. Figure
5.9 shows the number of monitor units per beam for both treatment plans optimized for
a prostate cancer case.
The dose distributions for the different primary fluences are similar in terms of target
coverage, target conformity and OAR sparing for the prostate and anal cancer case. The
final dose distribution is shown in figure 5.13 for the anal cancer patient. DVHs comparing
both dose distributions for all cases are shown in figure 5.10, 5.11 and 5.12. The only case
showing visible difference for the two beam profiles was the oropharynx cancer patient
with an increased exposure to some OARs. Table 5.2 summarizes the results for the three
patients. For all cases the mean dose to the patient contour is higher for the non-flattened
beam profile.
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Figure 5.9: Number of monitor units
per beam direction for a treatment plan
optimized for a flattened beam profile
(green) and a non-flattened beam (red).
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Figure 5.10: DVH for a treatment plan
optimized with a flattened (solid lines) or
non-flattened (dashed lines) beam profile
for prostate cancer. The color code used
for the VOIs in all DVHs in this section
is the same as in section 4.2
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Figure 5.11: DVH for a treatment plan
optimized with a flattened (solid lines) or
non-flattened (dashed lines) beam profile
for an anal cancer patient. The color
code used for the VOIs in all DVHs in
this section is the same as in section 4.2
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Figure 5.12: DVH for a treatment plan
optimized with a flattened (solid lines) or
non-flattened (dashed lines) beam profile
for an oropharynx cancer patient. The
color code used for the VOIs in all DVHs
in this section is the same as in section
4.2
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prostate cancer anal cancer oropharynx cancer
flattened non-flattened flattened non-flattened flattened non-flattened
PTV
coverage 0.98 0.97 0.83 0.83 0.67 0.63
conformity 0.89 0.90 0.90 0.93 0.96 0.95
oar 1
D1% 70.5 68.3 42.5 44.3 53.1 54.8
mean 13.9 15.1 20.3 22.1 25.8 27.5
oar 2
D1% 75.4 74.3 46.3 47.6 23.5 25.4
mean 16.5 18.0 30.5 29.2 5.2 6.8
oar 3
D1% 46.8 46.8 25.7 27.7
mean 11.8 12.6 13.3 15.0
contour
mean 5.8 6.2 16.5 16.9 12.9 13.6
Monitor Units 479 534 450 606 483 687
Table 5.2: Comparison of treatment plans optimized with a flattened and non-flattened
beam profile. OAR 1, 2 and 3 are rectum and bladder for prostate cancer, genitals, bladder
and bowel for anal cancer and parotid glands, brain stem and spinal cord for oropharynx
cancer, respectively. Dose values are in Gy.
(a) with flattening filter (b) without flattening filter
Figure 5.13: Dose distribution in a transversal slice for a flattened beam profile (left) and
a non-flattened beam profile (right) for an anal cancer patient
56 5 Stability of AMCBT treatment plan quality
5.3 Variation of optimization and delivery parameters
In this section the influence of a variety of parameters on the dose distributions is ex-
amined. The quality of an AMCBT treatment plan depends upon other terms on the
parameters chosen for the optimization and on settings chosen for dose delivery. For a few
of these parameters it was investigated how they influence the final dose distribution. In
particular, the influence of the number of beam directions, the collimator angle, the leaf
width, a constant dose rate and the rotational interval for dose delivery were studied.
Naturally the quality of the dose distribution improves with increasing number of iter-
ations. Figure 5.15 shows the improvement of the objective function and the dose dis-
tribution during the direct aperture optimization. This chart starts after the gradient
optimization of the field weights for the initial field shapes has finished, thus 0 iteration
steps means the first iteration within the DAO part of the optimization. Therefore the
first display of the dose distribution after 5 iterations shows the dose distribution that
is achievable for the chosen initial field shapes if no direct aperture optimization would
be performed. A comparison of the dose distributions after 5 and 1000 direct aperture
optimization steps is shown in the dose volume histogram in figure 5.14. The much better
target coverage together with a better sparing of the bladder is clearly visible within this
DVH.
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Figure 5.14: Dose volume histogram for treatment plans optimized in 1000 iteration steps
(solid line) and 5 iteration steps (dashed line).
To get an impression of typical treatment fields for an AMCBT treatment figure 5.16
displays the fluence maps for a prostate cancer patient. Beside the shape of the field the
weight is displayed by different shades of gray. The beam´s eye view of the patient geom-
etry is shown for gantry angles of 45◦, 135◦, 225◦ and 315◦. This treatment was optimized
without the consideration of hardware limitations during the optimization. The treatment
fields at 50◦, 300◦ and 310◦ are not displayed because their weight was 0.
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Figure 5.15: Progression of the objective function and the quality of dose distributions
during the direct aperture optimization. Displayed VOIs are the PTV (pink), CTV (red),
PTV (red) and rectum (green).
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Figure 5.16: Treatment fields for AMCBT for a prostate cancer patient. The beam´s eye
view is shown for gantry angles of 45◦, 135◦, 225◦ and 315◦. The target is displayed in
pink, the rectum in green and the bladder in blue.
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5.3.1 Number of beam directions
The number of beams used for treatment planning influences the results of the dose op-
timization. With a small number of beam directions the sampling of the continuous
rotational delivery is poor and the number of DOF for optimization is low. On the other
hand treatment planning with a small number of beam directions is very fast and lim-
itations that are imposed by the delivery hardware do not restrict treatment planning
if the angular distance between beam directions is large. With a high number of beam
directions treatment planning becomes much slower and the limitations imposed by the
delivery hardware become more severe. Moreover the treatment planning hardware needs
a high memory capacity to store the dose information for a large number of beams.
Most plans shown in this thesis were optimized with 36 or 51 beam directions. For one
example it will be shown that 36 beams are sufficient to explore the full advantage of dy-
namic rotational therapy and that the sampling rate is sufficient to reproduce the dynamic
delivery.
Treatment plans with different numbers of beam directions were optimized for a prostate
cancer patient. The dose constraints and penalty factors were the same for all treatment
plans, but the number of iterations was increased for the optimization with 72 beam di-
rections due to the larger number of DOF.
A comparison of treatment plans optimized with 18, 36 and 72 beam directions is shown
in figure 5.17. The reduction to 18 beam directions resulted in a worse coverage of the
target and a higher amount of dose to the rectum. For treatment plans optimized with 36
and 72 beam directions there are no visible differences for this patient anatomy.
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100 110 120
volume [%]
dose [%]
(a) 36 beams vs 18 beams
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100 110 120
volume [%]
dose [%]
(b) 36 beams vs 72 beams
Figure 5.17: Dose volume histogram for treatment plans optimized with 18, 36 or 72 beam
directions. Displayed are the GTV (red), PTV( pink), rectum (green) and bladder (blue).
The solid line represents the treatment plan which was optimized with 36 beam directions.
This example shows that increasing the number of beam directions for treatment planning
to 72 does not improve the quality of the dose distribution. Still, 36 beam directions might
not be sufficient to be consistent with the continuously delivered dose distribution. The
dose will be delivered while the gantry rotates and therefore the fixed beam directions
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used for planning will be smeared over 10◦ intervals (for the 36 beam plan). For a better
approximation of the dynamic delivery the field shapes and weights that were optimized
for 36 beams are interpolated to 360 beams. For this case there was no difference between
the DVHs for 36 and 360 beam directions.
For most beam directions the interpolation of MLC leaf positions is done linearly. If the
leaves have to move across an OAR this would lead to an increased dose to this OAR. To
reduce the dose to the OAR, all leaf pairs are closed before they move across the OAR.
The maximum leaf speed was considered in this step. An example showing this effect is
presented in figure 5.18 for a paraspinal tumor. At a gantry angle of 230◦ the open field is
on the left side of the target in the beam´s eye view. The next open field at 240◦ is on the
right side of the target. If the leaf positions are linearly interpolated, the open radiation
field would irradiate the spinal cord instead of the target. This leads to an increased dose
to the spinal cord, as shown in the DVH. If the leaves are closed before they move across
the OAR the differences in the DVH are much smaller. There is a slight decrease of dose
coverage in the target volume, but the dose to the spinal cord is even lower compared to
the original treatment plan.
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Figure 5.18: Effect of closing the leaves while they have to cross an OAR during dose
delivery. The solid line represents the original treatment plan optimized with 36 beam
directions, the dashed line the treatment plan that was interpolated to 360 beam directions.
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5.3.2 Collimator angle
For AMCBT a constant collimator angle is assumed during dose delivery, but each treat-
ment could be performed with a different collimator angle. By rotating the collimator the
direction of leaf movement could be changed.
Currently there is no optimization of the collimator angle included in the optimization
concept. To consider different collimator angles during the treatment plan optimization
it would be necessary to calculate an influence matrix for each collimator angle, which
would be too slow and too memory intensive. That the collimator angle has an effect on
the final dose distribution is shown in figure 5.21.
(a) 0◦ (b) 90◦ (c) 45◦
Figure 5.19: Schematic illustration of target conformal leave positions for different colli-
mator angles.
There are several aspects that have an influence on the choice of the optimal collimator
angle. By rotating the collimator the number of open leaf pairs and therefore the number
of degrees of freedom available for planning might vary, as pointed out in the schematic
illustration of a tumor and MLC leaves for different collimator angles (see figure 5.19). For
this elliptical shaped target geometry the number of open leaf pairs for a collimator angle
of 0◦ is higher compared to a collimator angle of 90◦. Another aspect is the matching of
the leaves to the target volume and therefore the amount of normal tissue that is unnec-
essary irradiated to high doses. As visible in figure 5.19 there is much more unnecessary
irradiated tissue for a collimator angle of 90◦ compared to 0◦. Other aspects that might
have an influence on the final dose distribution but were not yet investigated are interleaf
leakage or the tongue and groove effect.
A promising approach to determine the collimator angle was to calculate the number of
open leaf pairs for each collimator angle and to define the ”optimal” collimator angle as
the one with the highest number of open leaves. Based on the contoured volumes for the
respective case an algorithm calculates the initial field shapes for all gantry angles and
counts the number of open leaf pairs for each collimator angle in steps of 10◦. In figure
5.22 the mean number of open leaf pairs per beam direction is displayed as a function of
the collimator angle. As expected, by rotating the collimator for 180◦ the number of open
leaf pairs is approximately the same.
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(a) Collimator angle 0◦ (b) Collimator angle 90◦ (c) Collimator angle 200◦
Figure 5.20: Beam´s eye view at 0◦ gantry angle showing the MLC leaf positions after
optimization for different collimator angles.
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Figure 5.21: DVH for different collimator angles. The solid line represents a collimator
angle of 0◦, the dashed line 90◦ and the dotted line the ”optimal” collimator angle of 200◦.
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Figure 5.22: Average number of open leaf pairs per beam direction for different collimator
angles.
For the prostate patient the ”optimal” collimator angle is 200◦ with on average 15.9 open
leaf pairs per beam direction. But for this case the number of open leaf pairs for a col-
limator angle of 0◦ is almost the same and both collimator angles lead to the same dose
distribution. The beam´s eye view for different collimator angles in figure 5.20 shows that
for a collimator angle of 90◦ the number of open leaf pairs is much lower compared to a
collimator angle of 0◦ or 200◦. Treatment planning with a collimator angle of 90◦ leads to
a worse dose distribution, as shown in the DVH in figure 5.21.
Even though the approach to calculate the collimator angle based on the number of open
leaf pairs is not very sophisticated, it can help to find a good collimator angle. Most plans
in this work were optimized with a collimator angle of 0◦.
5.3.3 MLC leaf width
The MLC leaf width determines the size of the bixels used for treatment planning. KonRad
works with square bixels, where the bixel size corresponds to the MLC leaf width. The
current planning approach with a precalculated influence matrix storing dose contributions
for all bixels has the disadvantage that a dose calculation is only possible for field shapes
that are made up of a multiple of the bixel size. Therefore, all field shape changes are at
least one bixel in size even though in leaf movement direction smaller steps might lead to
better dose distributions.
Treatment plans were calculated for (2.75 mm)2, (5 mm)2 and (10 mm)2 bixels. For the
generation of the initial field shapes the number of bixels overlapping with the projection
of the most important OAR increases with decreasing bixel size. The initial field shapes for
10 mm, 5 mm and 2.75 mm bixels consists of the bixel sets A
(2+)
k , A
(2++)
k and A
(2++++)
k ,
respectively. Figure 5.23 shows the DVHs for all three treatment plans. For a similar dose
distribution in the target the dose to the OARs increases with increasing bixel size, e.g. the
mean dose in the rectum is 24.7 Gy, 25.1 Gy and 30.1 Gy. The final value of the objective
function for the different bixel sizes was 39036, 43026 and 54498 for 2.75 ∗ 2.75mm2,
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5 ∗ 5mm2 and 10 ∗ 10mm2 bixels, respectively.
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Figure 5.23: DVH for different bixel sizes. The solid line represents the dose distribution
calculated with (5 mm)2 bixels, the dashed line (10 mm)2 and the dotted line (2.75 mm)2.
Displayed are the GTV (red), PTV( pink), rectum (green) and bladder (blue).
5.3.4 Constant dose rate
In AMCBT the dose rate can vary within a specified range during dose delivery. To
perform AMCBT the ability to vary the dose rate or gantry rotation speed of the linac
during dose delivery is required. In this section it is investigated by how much the quality
of dose distributions decreases if the dose rate is kept constant for the complete treatment.
To generate treatment plans with a constant dose rate, i.e. the same field weight for each
beam direction, the projection in the optimization algorithm was modified. Instead of
assigning an individual weight to each field shape, the mean weight of all field shapes
is calculated and the same value is assigned to all field shapes. Therefore the weight is
not kept constant during the optimization process, but it is kept constant for all beam
directions.
For some cases, e.g. the prostate cancer patient that was considered in the last sections, a
constant dose rate does not lead to a degradation of the treatment plan quality. For this
example case the dose coverage and conformity of the target volume and also the dose to
OARs were almost the same for the treatment plans that were optimized with constant
and variable dose rate.
In figure 5.24(a) the influence of removing the degree of freedom to vary the dose rate
during dose delivery on the dose distribution for another prostate cancer case is shown.
The dose coverage of the target volume is worse if no variation of the dose rate is allowed
and the dose to the bladder is higher. The dose that is delivered to the rectum is lower
for the constant dose rate.
5.4 Sensitivity of rotational therapy to dose delivery errors 65
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90
volume [%]
dose [Gy]
(a) DVH
0
2
4
6
8
10
12
14
0 100 200 300 400 500 600 700 800 900 1000
Number of
iterations
Objective function value
(b) Objective function
Figure 5.24: Comparison of treatment planning with constant or variable dose rate for a
prostate cancer patient. In the DVH the dose distribution that was optimized with variable
field weights is represented by the solid lines, the one optimized with constant dose rate
is represented with dashed lines. The green curve shows the progression of the objective
function for a constant dose rate, the blue one for variable dose rate.
The difference between the dose distribution and the prescribed dose values is measured
with the objective function. Figure 5.24(b) shows the progression of the objective function
for the optimization with variable and constant dose rate. This chart starts after the first
stopping criteria in the optimization loop for AMCBT was fulfilled, thus after the field
weights for the initial field shapes were optimized. This explains why the objective function
at the beginning of this chart is much higher for the treatment plan with constant dose
rate. By varying the field shapes it is possible to improve the dose distribution achievable
with constant dose rate, but still with variable dose rate the objective function is lower.
5.4 Sensitivity of rotational therapy to dose delivery errors
The calculation of the dose distribution is based on a treatment plan that defines MLC
leave positions and a number of MUs for each beam direction. For a dose delivery with
fixed gantry angles the measured dose distribution will agree with the calculated distribu-
tion if all leaves are positioned correctly and the correct number of MUs is delivered per
beam. Also for a dynamic dose delivery the measured and calculated dose distributions
are expected to agree with each other. In this section the influence of several errors that
could occur during dose delivery on the dose distribution is investigated for a prostate
cancer patient. This analysis was also performed for other geometries with similar results.
5.4.1 MLC
The first possible source for dose delivery errors under investigation is the multileaf col-
limator. Leaves might be displaced systematically, e.g. all leaves are shifted in the same
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direction, or randomly, e.g. all leaves are displaced for different distances and in different
directions.
The influence of a systematic leaf shift on the dose distribution was tested for 1 mm, 2 mm
and 3 mm leaf displacements for several clinical cases. For random shifts leaf displace-
ments up to 5 mm were tested. In figure 5.25 a systematic and a random leaf displacement
for 3 mm are shown in the beam´s eye view. For random errors the leaf displacement was
either the same distance for each leaf, as shown in figure 5.25(d), or all leaves were dis-
placed randomly by distances between minus and plus the maximum displacement value.
The influence of leaf displacements on the dose distribution is displayed in figure 5.26. For
random shifts the imposed error on the dose distribution is small. Even for displacements
between -5 mm and +5 mm there were only minor differences in the DVHs. For systematic
leaf displacements there are much bigger differences in the dose distribution. Even for a
leaf displacement of 1 mm there are small differences in the DVHs. For a leaf displacement
of 3 mm the differences are clearly visible in the DVH. For both a leaf shift to the left and
to the right side the coverage of the target decreases. For the initial field shapes used for
this optimization the loss of dose coverage in the target is more pronounced for a shift to
the right side, whereas a shift of the leaves to the left increases the dose to the rectum.
(a) Original field shape (b) -3 mm (c) + 3mm
(d) + or - 3mm (e) 1 mm outside field (f) 1 mm inside field
Figure 5.25: leaf displacements in the beam´s eye view.
The size of the field was not changed in the last examples. If the field shape gets broader
or more narrow there is an effect on the dose distribution even for small displacements.
The DVH in figure 5.26(d) shows the influence on the dose distribution if all leaves are
shifted by 1 mm outside of the field, i.e. the left leaves move to the left and the right
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Figure 5.26: Influence of systematic and random leaf displacements on the dose distribu-
tion. The solid lines represent the original plan, the dashed lines the treatment plans with
displaced leaves. Displayed are the GTV (red), PTV( pink), rectum (green) and bladder
(blue).
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leaves to the right. In this case the dose to the target volume and the adjacent OARs
increases, e.g. the mean dose to the rectum increases from 23.8 Gy to 25.6 Gy.
For other clinical cases the results were the same - a systematic shift to one side results
in a worse dose distribution and randomly shifting the leaves for up to 3 mm has only a
small effect on the dose distribution.
5.4.2 Dose rate
In this section the effect of dose rate errors during dose delivery are examined. To generate
treatment plans with a dose rate that differs from the original treatment plan the number
of monitor units per beam was changed. The dose rate [MU/min] is calculated according
to:
DR = Number of MUs per beam ∗
vGantry
∆ϕ
with ∆ϕ as the angular interval between two beams.
At first the dose rate was increased or decreased for the complete treatment by approxi-
mately 1%. A comparison of the DVHs for the original treatment plan with 476 MU and
a treatment plan with 481 MU is shown in figure 5.27(a). The increase in the number of
MUs per beam is 0.14 MU, resulting in an dose rate increase of 1.6 MU/min for a gantry
rotation speed of 120 ◦/min.
An increased dose rate leads to additional dose in all VOIs, e.g. the mean dose that is
delivered to the GTV increases from 76 Gy to 76.8 Gy and the dose to the rectum from
23.8 Gy to 24 Gy. Moreover, the dose coverage of the target volume increases, but the
conformity of the dose distribution decreases. The integral dose that is delivered to the
patient increases from 127.5 Gyl to 128.8 Gyl.
As a result, a systematic dose rate error of 1% would lead to visible differences in the
DVH, but might not be detected in dose measurements. To account for setup errors and
other uncertainties in a dose measurement typically deviations between the measured and
calculated dose of up to 3% are tolerated.
In figure 5.27(a) a DVH for a treatment plan with an increased dose rate of 5% is shown.
The number of monitor units for this plan adds up to 500 MU. In this case the mean dose
to the GTV is increased to 80 Gy and the dose that is delivered to the rectum is 25 Gy.
For the next test the number of monitor units was increased for low dose rates and de-
creased for high dose rates, as shown in figure 5.28. The total number of monitor units is
the same for both treatment plans. The dose rate is changed by up to 23 MU/min. The
influence of this dose rate error on the dose distribution is shown in figure 5.27(c).
The integral dose for the modified treatment plan is slightly lower with 126.3 Gyl com-
pared to 127.5 Gyl. In some VOIs the dose is slightly increased for the treatment plan
with imposed dose rate errors, e.g. the mean dose that is delivered to the bladder increases
from 25.8 Gy to 26.3 Gy. Other VOIs receive a lower dose with the modified treatment
plan, e.g. the mean dose to the rectum is decreased from 23.8 Gy to 23.4 Gy. Overall, dif-
ferences between both treatment plans are small for dose rate errors of up to 23 MU/min
at maximum.
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Figure 5.27: Dose volume histograms for treatment plans with imposed errors in the dose
rate. The original dose distribution is displayed with solid lines, the modified with dashed
lines. Displayed are the GTV (red), PTV( pink), rectum (green) and bladder (blue).
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Figure 5.28: Number of Monitor Units per beam for the original treatment plan (red
curve) and the modified plans (blue and green curve).
Another treatment plan with dose rate errors of up to 68 MU/min was generated and the
resulting dose volume histogram is displayed in figure 5.27(d). The number of monitor
units per beam in comparison to the original treatment plan is shown with the green curve
in figure 5.28. In this case the integral dose is reduced to 124 Gyl and the dose coverage
of the target volume decreases from 0.86 to 0.77. Most VOIs receive less dose with the
modified treatment plan, only in the bladder the dose is increased to 27.2 Gy.
The effect of a constant dose rate during dose delivery on the dose distribution is shown
in figure 5.29. For the field shapes that were optimized with a variable number of mon-
itor units during optimization a dose delivery with constant dose rate would lead to an
unacceptable dose distribution. It should be noted that if a constant dose rate is assumed
for the treatment plan optimization a plan quality almost equal to the dose distribution
achievable with variable dose rate was possible for this patient.
5.4.3 Gantry position
As a last component that could lead to errors during dose delivery the influence of the
gantry position on the dose distribution is examined. AMCBT treatment plans were gen-
erated for a fixed number of beam directions and for these beams the number of monitor
units and the MLC positions were optimized. In this section the gantry angle of all beams
in the treatment plan is rotated for an angular interval. During dose delivery the dose rate
and MLC movement are controlled by the gantry angle, therefore a delay in processing
this information would lead to an angular displacement of leaf positions and dose rate.
Treatment plans with an error of the gantry angle of 1◦, 5◦ and 10◦ were calculated. The
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Figure 5.29: Comparison of the dose rate and dose distribution for a constant and variable
dose rate.
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Figure 5.30: DVH for treatment plans with an angular displacement of the MLC leaf
positions and dose rate. Displayed are the GTV (red), PTV( pink), rectum (green) and
bladder (blue).
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DVH for 5◦ and 10◦ are shown in figure 5.30. For 1◦ there was no visible difference in the
DVH curves of the original and the modified treatment plan.
A rotation of 5◦ leads only to small differences. For a 10◦ rotation the dose coverage of the
target decreases from 0.86 to 0.83 and the conformity of the dose distribution decreases
from 0.82 to 0.79. The dose to the OARs increases, e,g, the mean dose in the rectum is
26.1 Gy compared to 23.8 Gy for the original treatment plan.
6 Hardware solution for AMCBT
This chapter deals with the hardware solution for AMCBT on a Siemens accelerator. For
dynamic rotational dose delivery a linac with the ability to vary the dose rate during treat-
ment and an MLC with dynamic IMRT delivery capabilities are required - two features
which are not necessary for step and shoot IMRT. In this chapter the hardware solution
that was implemented at DKFZ is explained and the feasibility to perform arc-modulated
cone beam therapy is demonstrated.
To begin with, the components needed for dynamic rotation therapy are introduced sepa-
rately. The key components are the dose rate variation, the dynamic MLC and the gantry
rotation. Finally, these components are combined to perform rotation therapy with vari-
able field shapes and variable field weights. Different measurements were performed to
verify the dose distributions calculated for AMCBT treatment plans.
6.1 Dose rate modulation
Siemens accelerators normally operate with a constant dose rate, which is controlled by
the dose rate control voltage (DRCV). This value is adjustable in the linac control console
and depends on the selected machine parameters, e.g. the beam energy. During dose
delivery the actual dose rate is adjusted to the predetermined value by changing the pulse
repetition frequency (PRF). The principle of dose rate control is the following: while
radiation is on, the dose pulses are detected with a measurement device and converted to
a direct voltage. This voltage is compared to the predetermined DRCV. If the measured
value is smaller, the dose repetition rate is increased if it is larger the repetition rate is
decreased. With this circuit, the so called ”closed loop”, the dose rate is kept constant
during delivery.
6.1.1 Dose rate modulation board
The dose rate of the linear accelerator depends on the dose rate control voltage. By
changing the DRCV value during dose delivery it is possible to modulate the dose rate.
To allow for a patient specific variable DRCV during treatment, an electronic board was
developed in collaboration with Siemens which interrupts the DRCV signaling pathway
(see figure 6.1). As input, the board needs the cumulative dose for each gantry angle for
a specific treatment before starting the dose delivery. During delivery the board adjusts
the DRCV value to the specified value for each gantry angle. As a result, the dose rate is
modulated.
The following information is submitted to the DRCV modulation board:
• the total number of monitor units to be delivered (MUtotal)
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• the gantry rotation speed (vGantry)
• the start and stop angle for the arc (ϕstart, ϕstop)
• nominal values for the dose rate (DRstd) and DRCV (DRCVlinac)
• the dose rate modulation as a function of the gantry angle ϕ(normalized cumulated
dose NCD(ϕ))
The DRCV for each angle between ϕstart and ϕstop in steps of ∆ϕ = 1
◦ is calculated
according to:
DRCV (ϕ) =
DRCVlinac
DRstd
∗MUtotal ∗ vGantry ∗ (NCD(ϕ+∆ϕ)−NCD(ϕ))
The gantry rotation speed for a treatment is calculated in the linac control console based
on the total number of monitor units and the rotation interval. The correct total number
of MUs would lead to a fast gantry rotation speed, since the console does not know about
the dose rate modulation and assumes the maximum dose rate for dose delivery. For
example, if the rotation interval is 360◦ and the number of MUs 500 the console sets the
gantry speed to 216 ◦/min. To slow down the gantry rotation speed an adapted number of
MUs is entered to the control console which determines the correct gantry rotation speed
for a specific treatment. As a result, the dose delivery is not terminated by delivering the
correct number of MUs but by reaching the stop gantry angle.
Figure 6.1: Photograph of the dose rate control board (marked with red rectangle).
6.1.2 Experimental verification of dose rate modulation
The first step was to identify the limitations of the dose rate modulation, i.e. the maxi-
mum possible change of the DRCV value. The minimum and maximum achievable dose
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rates are not influenced by the DRCV board. The maximum dose rate of 300 MU/min
corresponds to a DRCV value of 7570 mV. To determine the maximum possible dose rate
modulation, the radiation was switched on with a constant DRCV and then this value is
changed manually within the software of the DRCV board. If changing the dose rate was
possible, the old DRCV value was set again and a bigger change was imposed. This was
done until the linac console reports an interlock. This experiment was performed with a
Siemens PrimusTM and a Siemens ArtisteTM accelerator. The results were similar, table
6.1 shows the maximum possible DRCV changes for the ArtisteTM linac. The first row
displays the initial DRCV value. The minimum and maximum DRCV that this value
could be changed to are denoted with DRCVmin and DRCVmax, respectively.
DRCV DRCVmin DRCVmax
1000 600 3100
2000 1200 5000
3000 1700 7570
4000 2400 7570
5000 3000 7570
6000 3700 7570
7000 4400 7570
Table 6.1: Maximum possible changes of the DRCV. All values are in mV.
How much the DRCV can change depends on the value of the DRCV and if the dose rate
should be increased or decreased. For an increasing dose rate bigger changes are possible.
For decreasing the dose rate the DRCV value could be reduced by approximately a factor
of 1.6.
For the first dosimetric measurements the field size was adjusted to 10 ∗ 10 cm2. As
measurement devices a PTW Farmer-type ionization chamber and the flat panel detector
of the ArtisteTM (Siemens Optivue 1000 ART) were used. The dose measured with the
ionization chamber was read every 500 ms. The maximum read out frequency of the panel
is 15 Hz.
For the first dosimetric measurements the dose rate was set to a constant value and a total
of 100 MUs were delivered. This was done for different DRCV values and the dose was
measured with an ionization chamber at the isocenter. For the chosen settings a total of
100 MUs should result in a dose of 1 Gy. Table 6.2 summarizes the results. The diagram
in figure 6.2 illustrates that the dose for the same number of MUs slightly increases with
higher DRCV values. Since the deviation is smaller than 0.5% this effect was not further
accounted for.
The progression in time of the DRCV value for two different dose rate levels is shown in
figure 6.3. The green curve shows the progression of the DRCV value without the DRCV
board interrupting the DRCV signaling pathway. The reason for the larger deviations of
the measured DRCV value from the specified value for the two curves with a DRCV of
7570 mV compared to the curve with a DRCV of 3000 mV are caused by an automatic
switch of the measurement range and the fixed number of digits transfered by the device
used to read out the ionization chamber (Unidos, PTW) over the serial interface after
76 6 Hardware solution for AMCBT
delivering more than 1 Gy. The shift in time of the three curves is of no importance,
because radiation was switched on at different times. After the first second the DRCV is
constant in time and the curves with and without the board interrupting the DRCV sig-
naling pathway do not show any difference. Also a lower DRCV of 3000 mV was adjusted
very accurately by the DRCV board.
DRCV [mV] dose [Gy]
1000 0.9996
2000 0.9981
3000 0.9994
4000 1.0010
5000 1.0015
6000 1.0025
7000 1.0025
7570 1.0038
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Figure 6.2: Measured dose for the delivery of 100 MUs with different DRCV values.
An eye-catching feature of figure 6.3 is the very high dose rate at the beginning of the
irradiation. After turning the radiation on, the linac operates in the so called ”open loop”,
in which the dose rate is not regulated as described before. Instead, the dose rate depends
on a nominal value set in the control console for the first second of the irradiation. There-
fore the DRCV values sent by the modulation board have no influence on the actual dose
rate. This could result in an over dosage at the beginning of the treatment. For example,
a treatment that was planned to start with a low dose rate of 60 MU/min (DRCV = 1514
mV) and instead starts with a high dose rate of 300 MU/min (DRCV = 7570 mV) would
result in the delivery of 6 MUs instead of 1 MU in the first second.
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Figure 6.3: A constant DRCV value of 7570 mV and 3000 mV set by the dose rate
modulation board over time. The green curve represents the progression of a constant
DRCV value without the board that interrupts the DRCV signaling pathway.
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To solve the problem of a high dose rate at the beginning of the treatment it is possible
to adjust the DRCV value for the open loop in the control console of the linac. There are
two issues that need to be respected: (1) The PRF set for the ”open loop” is fixed for the
first second of the treatment and therefore the dose rate is not modulated and (2) it is not
possible throughout the treatment to regulate the DRCV to values that exceed the initial
DRCV by more than 20%.
The first issue having no modulation of the dose rate in the first second of the treatment
is neglectable. The difference to the planned dose delivery is too small to affect the dose
distribution. The second issue is caused by a 20% limit control circuit within the linac
control system that avoids repetition rates in the ”closed loop” which exceed the value set
for the ”open loop” by more than +20%. Still, it is possible to change this setting during
treatment, as long as the current dose repetition rate is lower than the specified value.
Therefore only a treatment that would start with a low dose rate and continue with a
rapidly increasing dose rate would cause difficulties.
The next topic under investigation was the behavior of the dose rate while changing the
dose rate control voltage. For an accurate treatment it is necessary to examine how fast
the dose rate can change and what happens while it is changing. For this analysis treat-
ment plans starting with a constant DRCV and then changing rapidly to another DRCV
value were generated. This was performed for increasing and decreasing dose rates with
several different DRCV changes.
The best time resolution is possible with the flat panel detector, which was used for these
measurements. An example of one single frame recorded during irradiation is displayed in
figure 6.4. The stripes in the image are caused by differences in the dose pulse frequency
and the read out frequency of the panel. The panel is read out every 66.7 ms but the
interval between the dose pulses varies between 5 and 40 ms. During read out of the panel
the next dose pulse is fired and therefore this pulse is only registered in the pixels that
were not read out yet. To determine the DRCV value in each frame the mean value of all
pixels in a user defined area is calculated. For the correlation of the pixel values and the
DRCV values a calibration curve was measured.
The result of the image analysis is a DRCV value for each frame and thus the DRCV
as a function of time. The input data for the dose rate modulation is the normalized
cumulative dose against the gantry angle - and not time. To compare the measured and
prescribed DRCV a constant gantry rotation speed is assumed to calculate the prescribed
DRCV against time. This assumption is reasonable except for the beginning of the rota-
tion (see section 6.3). Since the calculation of dose delivery time from the gantry angle is
not accurate for the first second of the treatment there is a shift of the calculated values
against time. Therefore, in the following analysis it was assumed that no delay occurs for
sending the new DRCV value and the graph representing the planned DRCV value was
shifted in time so that the experimental data most closely matches the prescribed DRCV
curve.
Figure 6.5 shows a comparison of the planned and measured DRCV for two examples.
The measurement was repeated several times with different DRCV changes. Figure 6.5
shows that changing the dose rate results in an overshoot and undershoot of the DRCV
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Figure 6.4: Rectangular radiation field as measured with a flat panel detector.
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Figure 6.5: Comparison of the planned (red) and measured (blue, green, cyan) dose rate
control voltage for different DRCV changes.
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value, respectively. The amplitude of the oscillation varies for the different measurements.
For changing the DRCV from 2976 mV to 6959 mV the maximum overshoot of the DRCV
value is 13%, the maximum undershoot for the change from 5990 mV to 3974 mV is 30%.
The oscillation of the DRCV happens in a very short time interval, in the order of 200
- 400 ms. The same measurements performed with the ionization chamber and a time
resolution of 0.5 seconds do not show the overshoot or undershoot of the dose rate. This
oscillation will presumably not influence the final dose distribution and was therefore not
further investigated.
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Figure 6.6: Progression of the DRCV value for a prostate patient treatment. The red
curve displays the calculated DRCV values. The blue, green and cyan colored curves show
the measured DRCV.
Finally, the dose rate that was optimized for a prostate cancer treatment was delivered
without variation of the field shapes during dose delivery. The delivered dose was mea-
sured with the ionization chamber and with the flat panel detector. Figure 6.6 shows a
comparison of the measurement and the theoretical progression of the DRCV value. For
the measurement with the ionization chamber the dose was measured every 0.5 seconds
and the gantry rotation speed was 120 ◦/min. The treatment time for a 360◦ rotation
with vgantry = 120
◦/min is 180 sec. In this example the theoretical progression of the
DRCV value is plotted against the gantry angle (red curve and axis in figure 6.6(a)) and
the measured DRCV is plotted against time. If the gantry rotates with the specified
gantry speed then the time and gantry axes would correspond with each other (accord-
ing to t = 60 ∗ ϕ
vgantry
, ϕ denotes the gantry angle). There is a good agreement between
the prescribed and measured DRCV, but there is a small shift between the curves. This
difference in time stays constant for the whole treatment. Presumably it is caused by an
incorrect gantry rotation speed at the beginning of the treatment (see section 6.3).
For the measurement with the flat panel detector the gantry speed was 110 ◦/min, which
results in lower DRCV values. The integration time of the detector was 399 ms. The
curves in figure 6.6(b) were shifted in time to get the best agreement between measure-
ment and the theoretical progression of the DRCV value. This measurement confirms
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the feasibility of using the DRCV board to change the dose rate during dose delivery in
accordance to the planned dose rate.
6.2 MLC control
In this section the dynamic performance of a Siemens 160MLCTM was tested for rotation
therapy. This MLC consists of 80 leaf pairs with an isocentric leaf width of 5 mm and a
maximum field width of 40∗40 cm2. For step and shoot IMRT the movement of the MLC
leaves takes place while the radiation is off, therefore the behavior of the leaves during
movement is of no importance. For arc therapy the leaves move during irradiation and
therefore they need to move to a specified position without (or with as little as possible)
delay. During his PhD thesis project Martin Tacke worked on software and hardware
developments to realize dynamic control of the MLC to realize tumor tracking with this
MLC. The system architecture for the MLC control is described in his thesis [57]. The
dynamic MLC control system was used for the realization of dynamic arc therapy.
In contrast to a tracking approach in which the movement of the patient is not known
before the treatment the leaf positions for arc therapy are a priori known. The informa-
tion of the leaf positions are read from the plan file. The program that controls the MLC
movement (TrackingTool) linearly interpolates leaf positions for each gantry angle within
the rotational interval in steps of 0.1 degree. During treatment the program receives the
actual gantry angle and sends leaf positions for this angle to the MLC control console.
The leaves of the MLC are mounted on carriages. For a fixed carriage position the leaves
can move a maximum distance of 20 cm to each side. So far the movement of the carriages
is not considered within the MLC control software, and therefore the maximum radiation
field size that is adjustable with the MLC is 20 ∗ 40 cm2.
To verify the MLC leaf movement during treatment two methods were used. Treatments
were recorded with a flat panel detector and the movement of the leaves as visible on
the panel images was compared to the planned positions. Moreover, during treatment
the TrackingTool logs the gantry angle, the planned leaf position and the ”real-time” leaf
position, e.g. the position of the leaves during treatment. This information was also used
to determine the positioning accuracy of the leaves during treatment.
The agreement of the planned and ”real-time” positions of the leaves as logged by the
TrackingTool software is good in most cases. The overview of the movement of leaf pair 40
in figure 6.7(a) shows that the leaves start moving as soon as the gantry starts to rotate.
The agreement between the planned and ”real-time” positions looks good in this figure.
A more detailed view is given in figure 6.7(b). Here it is visible that at the turning points
the ”real-time” positions slightly deviate from the planned positions. The reason for this
is a prediction algorithm which is necessary to account for the systems latency and delay
times. The time needed from sending a new leaf position until the leaves start to move to
this position is about 400 ms. Therefore it is necessary to employ a prediction algorithm
to calculate the next position of the leaves and send this information before the rotation
angle for this field shape is reached. In the current implementation this leads to small
deviations at extreme points of the MLC movement.
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Figure 6.7: Comparison of the planned (green and red curve) and realized (black curve)
movement for one leaf pair. The position of the gantry is displayed with the blue curve.
The data was recorded during treatment with the MLC control software.
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Figure 6.8: Comparison of the planned (green and red curve) and realized (black curve)
movement for one leaf pair. The data was recorded during treatment with the a flat panel
detector and processed afterwards in MatLab.
The above example treatment was also recorded with the flat panel detector. Radiation
was switched on with a constant dose rate. The linear correlation between leaf positions
and the radiation field on the image was determined before the measurement. Therefore a
set of rectangular radiation fields with known size were imaged with the detector and the
correlation of the MLC leaf positions and the start and stop pixel of the radiation field
determined. In figure 6.8 the leaf movement for one leaf pair is shown. This also confirms
an agreement between planned and measured leaf positions.
Lastly, the leaf movement for an optimized treatment plan for a prostate cancer patient is
shown in figure 6.9 for two leaf pairs. Also for this more complicated leaf movement the
agreement between measured and planned leaf positions is good.
6.3 Gantry Rotation
For arc-modulated cone beam therapy a continuously rotating gantry with constant rota-
tion speed is necessary. During treatment plan optimization the gantry speed is calculated
from the total number of MUs for a specific plan, as described in section 3.2. A slow gantry
rotation speed, e.g. 50 ◦/min, allows for large MLC movements and a high number of mon-
itor units per beam direction. With a faster rotating gantry the treatment time decreases,
but the restrictions on MLC movement and the maximum number of MUs are more severe.
A variable gantry speed would increase the flexibility in arc therapy treatment planning,
but for delivery this would also increase the complexity.
During treatment the gantry position is recorded every 100 ms. The dose rate modulation
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(b) Leaf pair 41
Figure 6.9: Comparison of the planned (green and red curve) and realized (black curve)
movement for an optimized prostate treatment plan. The position of the gantry is displayed
with the blue curve. Data was recorded with the MLC control software during treatment.
board taps the gantry signal at the linac backplane and sends it to a PC in the control
room. Depending on the current gantry angle the dose rate and MLC leaf positions are
adjusted as stated in the plan file. Since the dose rate and leaf positions depend on the
gantry angle, it is important that the gantry rotates with the correct constant speed.
In figure 6.10 the measured gantry positions are plotted against time for different rotation
speeds. For comparison, the dashed lines represent calculated gantry positions for the
specified gantry rotation speed which were shifted in time to best match the measured
gantry position data. For all gantry speeds the measured gantry positions agree well with
the calculated ones. Figure 6.11 shows the comparison of the calculated and measured
positions for a shorter time period. During rotation both curves are in good agreement,
but at the beginning of the rotation there are larger differences between the measured and
calculated angular positions. To start moving the heavy gantry it needs some time to level
off at the specified speed. As visible in figure 6.11 the correct gantry speed is reached after
approximately one second, so the overall influence of the slower or faster gantry rotation
speed at the beginning of the rotation on the complete single arc dose delivery seems to
be negligible.
For all measurements the MV flat panel detector was moved out at a source imager dis-
tance of 145 cm. For this setting the movement of the gantry agrees best with the specified
speed. In figure 6.12 the movement of the gantry is shown with and without the MV panel
in position. If the panel is not retracted the speed of the gantry fluctuates, as visible for
the blue curve in figure 6.12.
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Figure 6.10: The solid lines represent the measured gantry positions for different rotation
speeds. As a comparison the dashed lines represent calculated gantry positions for the
specified gantry rotation speed.
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Figure 6.11: Amplification of figure 6.10 for the beginning of the rotation and during
rotation.
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Figure 6.12: Measured gantry positions versus calculated gantry positions for a rotation
with the MV panel extracted (red) and retracted (blue).
6.4 Dosimetric verification of AMCBT delivery
6.4.1 Methods and materials
For the verification of the dose distributions calculated for AMCBT measurements were
performed with phantoms that were either equipped with films or with ionization cham-
bers. Both phantoms had almost the same geometry: a cylinder with a diameter of 20 cm
consisting of 1 cm thick RW3 plates bolted together on two plexiglass rods. Figure 6.13(a)
shows the phantom with the first film put between two RW3 plates. With the holes in
the RW3 plates it is possible to mark the film and define the same coordinate system
on the film as on the transversal slice of the calculated dose distribution. For the film
measurement gafchromic EBT films were used. To analyze the measured dose distribution
and to compare it with the calculated dose distribution the software VerisoftTM by PTW
was used. Only a relative comparison of the dose distributions was performed for the film
measurement. For an absolute dosimetric verification the ionization chambers were used.
A difference between both phantoms is the position of the plexiglass sticks - they are
rotated by 90◦. The phantom that could be equipped with multiple ionization chambers
is displayed in figure 6.13(b). 25 notches allow the insertion of ionization chambers into
the cylindrical phantom. The photograph shows a phantom that is equipped with 5 ion-
ization chambers. The chambers are read out with the PTW MultidosTM multi-channel
dosemeter. If the phantom is aligned with the room lasers the middle notch corresponds
to the gantry rotation axis. Within the coordinate system of the phantom this notch has
the coordinates x = 0 mm and y = 0 mm. All other notches are separated by 20 mm.
For the dose measurements two different treatment plans were used. In the first treatment
the dose rate decreases and the MLC leaves move back and forth as seen in figure 6.7 for
a gantry rotation of 240◦. The second treatment plan was optimized for a prostate cancer
patient. Field shapes and weights from this treatment plan were copied to the phantom
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(a) Phantom for film measurement (b) Phantom equipped with ionization chambers
Figure 6.13: Phantoms used for dose measurements.
geometry and the dose distribution was recalculated. The gantry speed for a 360◦ rotation
is vGantry = 144
◦/min. The dose distributions for both treatments are shown in figure
6.14.
(a) Treatment 1 (b) Treatment 2
Figure 6.14: Dose distributions for the treatment plans used for dosimetric verification
of AMCBT dose delivery.
6.4.2 Results 1: multi-ionization chambers
Table 6.2 displays the dose values that were calculated for treatment plan 1 for all possible
x-y-coordinates of the ionization chambers for the slice in the isocenter (z = 146). Profiles
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in x- and y-direction for y and x positions of -40 mm, -20 mm, 0 mm, 20 mm and 40 mm,
respectively, are displayed in figure 6.15. The measured values and the deviations from
the calculated doses are reported in table 6.3 for 3 measurements.
Spalte1 -40 -20 0 20 40
40 0.663 0.795 0.601 0.382 0.261
20 1.077 0.832 0.293 0.22 0.207
0 1.371 0.626 0.106 0.094 0.157
-20 1.422 1.458 0.775 0.595 0.484
-40 1.026 1.357 1.138 0.716 0.441
y
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te
x-coordinate
Table 6.2: Calculated dose values for treatment 1. Dose values are given in Gy, coordi-
nates in mm.
(a) Measurement 1
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(b) Measurement 2
Spalte1 -40 -20 0 20 40
40
20 0.835 0.273
0 1.331 0.115
-20 1.371
-40
x-coordinate
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Spalte1 -40 -20 0 20 40
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20 0.4 -6.7
0 -3.0 8.8
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(c) Measurement 3
Spalte1 -40 -20 0 20 40
40 0.627
20 1.058 0.204
0 0.112
-20 1.463
-40
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te
x-coordinate
Spalte1 -40 -20 0 20 40
40 4.3
20 -1.7 -7.1
0 5.8
-20 0.4
-40
y
-c
o
o
rd
in
a
te
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Table 6.3: On the left side the measured dose values for treatment plan 1 for 3 measure-
ments are shown (values are in Gy). On the right side the percentage deviation of the
measured value from the calculated value is displayed (in %).
The first measurement shows an acceptable agreement between the measured and calcu-
lated dose values for high doses, but for dose values below 0.3 Gy the percentage deviation
exceeds 5%. The results of the second measurement are in good agreement with the first
measurement. For the third measurement the positions of the ionization chambers was
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changed. As seen before, there is a good agreement for high dose values but too large
deviations in the low dose region.
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(a) Profiles in x direction
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Figure 6.15: Calculated dose profiles along the possible positions of the ionization chamber
in the phantom. The profile in x direction at a y position of -40 mm is displayed in blue,
-20 mm in red, 0 mm in green, 20 mm in cyan and 40 mm in black. For profiles in y
direction the same colors are used.
For the second treatment plan the comparison of the measured and calculated dose values
for several ionization chamber positions is displayed in table ??. For this treatment the
z-position of the chambers was also varied between measurements. Most measurements
were performed with the chambers positioned in the isocenter plane at z = 146. For a
maximum acceptable deviation of 5% all measured dose values agree with the calculated
dose values. Those chamber positions that were repeatedly measured showed a very good
reproducibility of the dose delivery, e.g. the dose measured with the chamber at the
isocenter was 2.072 Gy, 2.098 Gy, 2.095 Gy and 2.095 Gy.
For the second treatment plan there was an improved agreement of the measurements
with the calculated dose values. This might be caused by the fact that most dose values
were higher compared to the dose values of treatment plan 1 and moreover dose gradients
are not as steep as for the first treatment plan (see figure 6.18).
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Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 40 40
20 1.927 2.020 20 1.980 2.116 20 2.8 4.8
z = 156 mm 0 1.753 2.107 0 1.745 2.127 0 -0.4 1.0
-20 1.568 -20 1.583 -20 1.0
-40 -40 -40
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 40
20 1.910 1.948 20 1.990 2.032 20 4.2 4.3
z = 136 mm 0 1.597 2.058 0 1.571 2.083 0 -1.6 1.2
-20 1.293 -20 1.254 -20 -3.0
-40 -40 -40
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 40 40
20 1.936 1.982 20 1.959 2.060 20 1.2 3.9
z = 146 mm 0 1.663 2.063 0 1.641 2.072 0 -1.3 0.4
-20 1.337 -20 1.302 -20 -2.6
-40 -40 -40
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 40 40
20 20 20
z = 146 mm 0 2.015 2.063 2.026 0 2.079 2.098 2.072 0 3.2 1.7 2.3
-20 1.177 -20 1.205 -20 2.4
-40 0.271 -40 0.272 -40 0.2
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 0.535 40 0.551 40 3.1
20 1.395 1.854 20 1.428 1.899 20 2.3 2.4
z = 146 mm 0 2.063 0 2.095 0 1.5
-20 1.535 -20 1.551 -20 1.0
-40 -40 -40
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 0.535 40 0.549 40 2.7
20 1.395 1.854 20 1.428 1.900 20 2.4 2.5
z = 146 mm 0 2.063 0 2.095 0 1.5
-20 1.535 -20 1.554 -20 1.2
-40 -40 -40
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 0.476 40 0.478 40 0.4
20 1.274 1.738 20 1.236 1.757 20 -2.9 1.1
z = 166 mm 0 2.134 0 2.153 0 0.9
-20 1.786 -20 1.781 -20 -0.3
-40 -40 -40
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 0.772 40 0.806 40 4.4
20 1.373 1.953 20 1.408 1.991 20 2.5 1.9
z = 156 mm 0 2.107 0 2.123 0 0.8
-20 1.742 -20 1.766 -20 1.4
-40 -40 -40
Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40 Spalte1 -40 -20 0 20 40
40 0.559 40 0.536 40 -4.1
20 1.351 1.935 20 1.382 1.879 20 2.3 -2.9
z = 136 mm 0 2.058 0 2.040 0 -0.9
-20 1.494 -20 1.525 -20 2.1
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Table 6.4: Comparison of the calculated and measured dose for 9 measurements with
treatment plan 2 for different positions of the ionization chambers. The left row displays
the calculated dose [Gy], the middle column the measured dose [Gy] and in the right column
the deviation is shown [%].
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6.4.3 Results 2: film measurement
The film measurement was performed for the same two treatment plans. For these mea-
surements only a relative comparison of the dose values is performed. Figure 6.16 shows
the results for the first measurement. Displayed are the calculated dose distribution, the
measured dose distribution, the gamma index and a comparison of both dose distributions.
(a) calculated dose distribution (b) measured dose distribution
(c) gamma index (d) comparison of dose distributions
Figure 6.16: Film measurement for treatment plan 1. In the comparison of the dose
distributions the dashed line represents the calculated dose distribution, the solid line rep-
resents the measured dose distribution.
The criteria for the calculation of the gamma index were a local dose difference of 3% and
a distance to agreement of 3 mm. Dose values below 5% of the maximum dose in the cal-
culated dose distribution were excluded from the comparison. Otherwise the area around
the phantom would not pass the gamma test because no dose was calculated outside of
the phantom, but a low dose was delivered to the film. The dose distributions are very
similar, only in the low dose area there are some parts not passing the gamma test.
In figure 6.17 dose profiles along the x-axis and y-axis are shown. In the profile along the
y-axis the agreement between measured and calculated dose is good. Differences for high
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doses are visible in the profile along the x-axis. The peak in the measured profile along
the x-axis is a result of labeling the film with a needle to define a coordinate system.
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Figure 6.17: Dose profiles for film measurement 1. The measured profile is plotted in
blue, the calculated in red.
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Figure 6.18: Dose profiles for film measurement 2. The measured profile is plotted in
blue, the calculated in red.
The results of the second measurement are displayed in figure 6.19 and 6.18. Within the
target volume the agreement of the measured and calculated dose values is within the ac-
ceptance criteria of the gamma test. For this measurement there is an increased deviation
between the measurement and calculation within the low dose area. This is also visible in
both dose profiles.
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(a) calculated dose distribution (b) measured dose distribution
(c) gamma index (d) comparison of dose distributions
Figure 6.19: Film measurement for treatment plan 2. In the comparison of the dose
distributions the dashed line represents the calculated dose distribution, the solid line rep-
resents the measured dose distribution.
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6.5 Discussion
The measurements described in this chapter have shown the feasibility to perform arc-
modulated cone beam therapy with a Siemens ArtisteTM linac. By using the DRCV
modulation board it is possible to vary the dose rate during dose delivery in good agree-
ment with the prescribed DRCV values. Within the limits imposed by the linac the dose
rate could be changed quickly and accurately during treatment. For challenges such as the
high dose rate at the beginning of the treatment a solution was presented. The rotation of
the gantry during treatment is constant with the specified speed, except in the beginning
of the rotation there are deviations from the specified gantry speed. An idea of how to
avoid dose delivery errors imposed by a wrong gantry rotation speed at the beginning of
a treatment is to start rotating the gantry a few degrees before starting the irradiation.
It was shown that the dynamic control of the MLC is feasible and that there is a good
agreement of the planned and realized leaf positions during treatment.
Even though it is feasible to perform dynamic rotation therapy with variable dose rate
with the Siemens ArtisteTM linac there are further issues that need to be addressed in
more detail. Especially for low doses there were differences between the measured and
calculated dose values. One possible explanation for this is leakage radiation through the
closed MLC leaves. Examples for three treatment fields for the prostate treatment plan
are displayed in figure 6.20. These images show that there is a gap between closed leaves.
The radiation coming through this gap might be a reason for an increased dose, which
will be most pronounced in areas receiving low doses during a treatment.
In this example the leaves are closed at x = 0. To reduce the influence of leakage radiation
through closed leaves it is better not to place them in the center of the field.
(a) frame 100 (b) frame 110 (c) frame 150
Figure 6.20: Treatment fields for a prostate cancer treatment imaged with a flat panel
detctor. The time between image frames is 399 ms. At x=0 leakage radiation is coming
through the closed leaf pairs.
Both the dose rate modulation board and the modified control unit for the MLC are re-
search developments which are not approved for patient treatments. Therefore the hard-
ware realization for AMCBT described in this chapter is not certified for clinical use.
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7 Discussion and conclusions
Arc-modulated cone beam therapy is a dose delivery technique that uses variable field
shapes and field weights during irradiation. In this thesis an optimization concept for
AMCBT was introduced. This treatment plan optimization algorithm was used to as-
sess the treatment plan quality achievable for AMCBT against other intensity-modulated
treatment techniques. Moreover the sensitivity of the plan quality for different hardware
and planning related aspects was investigated. A dose delivery solution employing a dose
rate modulation board and a dynamic MLC was developed and tested during this thesis
project.
Optimization concept
The optimization concept presented in this thesis is a direct aperture optimization algo-
rithm. Therefore field shapes and field weights are optimized directly and no sequenc-
ing step is required before the dose delivery. The mathematical optimization of the field
weights is performed with a gradient algorithm and for the optimization of the field shapes
a tabu search is used. The ability of the algorithm to obtain dose distributions of good
quality was shown in this thesis.
For AMCBT there is only one aperture per beam direction. To use the same DAO concept
for the optimization of treatment plans for fixed gantry IMRT the algorithm was extended
to allow for several apertures per beam directions. First results have shown a sensitivity of
the algorithm on the choice of the initial solution used for DAO planning for fixed gantry
IMRT. Starting with target conformal field shapes does not result in clinically acceptable
treatment plans. It is assumed that by choosing different initial aperture shapes the gener-
ation of treatment plans with a dose distribution quality similar to bixel weight optimized
treatment plans is possible for fixed gantry IMRT. Presumably a reduction of the number
of monitor units is possible with a DAO algorithm.
Limitations that are imposed by the dose delivery hardware were considered within the
optimization concept. A detailed description of the implementation was given in section
3.2. There are mainly two assumptions made for this implementation which might not be
the best choice for all cases. First, the treatment plan specific gantry speed depends on
the weights of the beams and thus the number of monitor units that needs to be delivered
within the angular interval between two beams. This approach is reasonable, for the de-
livery of a larger number of MUs the gantry needs to rotate slower. A treatment plan with
a total of 500 MU could not be delivered with a dose rate of 300 MU/min and a gantry
rotation speed of 360◦/min in a gantry rotation of 360◦. Even with vGantry = 216
◦/min
there would be no modulation of the dose rate possible if a total of 500 MU is required for
a single arc treatment. Therefore, the gantry speed is calculated based on the mean dose
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rate achivable with the linac and the number of MUs. The drawback of this approach is
that it does not consider the complexity of a specific patient geometry and the amount
of modulation needed to find the best treatment quality. Second, the gantry speed is
calculated only once in the optimization. This is done after the weights for the initial field
shapes were optimized and the first stopping criterium in the optimization algorithm is
fulfilled. This approach is based on some example cases for which the sum of all weights
at this point of the optimization was compared to the final value. For these cases the sum
was similar. Still, for other cases there might be a bigger change during the optimization
and it would be beneficial to calculated a new gantry speed during the optimization.
Limitations imposed by the MLC leaf speed did not lead to a degradation of the plan qual-
ity for any of the cases considered during this thesis project. In section 5.1 it was shown
that for some cases the range of the dose rate stated above is not sufficient to completely
exploit the potential advantages of dynamically modulated rotation therapy. The amount
of modulation that was assumed for this analysis was estimated before implementing the
dose rate modulation board. The measurements have shown that a restriction of the dose
rate variation to 20 MU/min per second is possibly not necessary and that this limitation
should be reconsidered. Experiments that were performed to find the maximum possible
change of the dose rate showed that this value depends on the value of the DRCV. There-
fore it might be better to include a percentage dose rate variation limitation instead of a
fixed value.
Treatment plan quality
AMCBT treatment plans were assessed in comparison to fixed gantry IMRT treatment
plans, to helical tomotherapy treatment plans and to ”idealized IMRT” treatment plans.
In comparison to fixed gantry IMRT the treatment plan quality achievable with AMCBT
was at the same level. A benefit of AMCBT - besides reducing the time to treat a patient
- was a lower number of MUs required for a specific treatment. This statement was made
in a number of papers, e.g. for prostate cancer treatments the number of MUs could be
reduced by up to 75% in one study [25], another studied showed a reduction from 1819 MU
for IMRT to 949 MU for RapidArc [48]. For head and neck cancer a the number of MU
decreased by nearly 60% [68] and for an integrated boost radiotherapy for bilateral breast
treatments the monitor units were reduced from 1398±301 MU for IMRT to 796±121 MU
for RapidArc [34], just to give a few examples. All these studies compared IMRT treatment
plans that were planned with the traditional two step approach and RapidArc treatment
plans generated with a DAO algorithm. Several studies comparing treatment plans for
fixed gantry IMRT that were either optimized in two steps or with DAO also showed a
reduction in MUs with DAO planning [51], [17], [66], [3], [13], [24]. However, one should
compare DAO optimized fixed gantry IMRT plans with dynamic rotation therapy to fairly
address the issue of required MU.
The comparison of AMCBT and ”idealized IMRT”, i.e. treatment plans that were opti-
mized with the same number of beams but intensity-modulated fluence fields, showed for
highly complex target geometries a benefit of intensity-modulated fields even for a high
number of beam directions. Therefore a dose delivery in several arcs might lead to a better
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treatment plan quality compared to a single arc. The number of arcs needed to get the
optimal treatment plan quality was not examined yet.
The focus in the assessment of the treatment plan quality achievable with AMCBT was on
the comparison with helical tomotherapy. The good dosimetric qualities of tomotherapy
were demonstrated in several previous studies. For the first type of cancer considered in
this study - prostate cancer - the dose distributions optimized for arc therapy were at least
as good as plans optimized for tomotherapy. Moreover single arc therapy has the advan-
tages of a faster dose delivery and a lower integral dose. From a shortened treatment time
the patient can benefit in terms of comfort and less risk of organ movement. Moreover
the patient throughput can be increased.
For the anal cancer patients the quality of the dose distribution was better for tomotherapy
than for AMCBT. With helical tomotherapy, there is an improved sparing of the genitals
and a very good dose coverage of the tumor. Nonetheless, the quality of dose distribu-
tions for single arc therapy is also of a high quality and seems to be clinically acceptable.
Possibilities to further improve the quality of arc therapy could be the use of several arcs
or non-coplanar beams. This would result in longer treatment times, but presumably the
treatment time would still be shorter compared to the 10 minutes needed for tomotherapy.
For the group of patients with a tumor in the head and neck region the treatment time
for tomotherapy also exceeds 10 minutes. The very high dose gradients achievable with
tomotherapy are especially helpful for the sparing of the parotid glands in close proximity
to the boost volume. Moreover a very low dose to the normal tissue in the neck is possible
with helical tomotherapy. With single arc therapy the dose to most organs at risk is higher
compared to tomotherapy.
To summarize this treatment plan comparison study, the plan quality of tomotherapy
treatment plans was not achieved with AMCBT therapy for all cases. For many clini-
cal cases single arc therapy will offer a very good plan quality, e.g. for prostate cancer,
whereas for very complex cases the dosimetric quality provided by tomotherapy was not
achieved with AMCBT. Whether this is an inherent limitation of arc therapy in a single
rotation or if the dose distribution could be improved with another optimization approach
is a question of future research. However, the dose distributions achievable with single
arc therapy seem to be also clinically acceptable for many cases. Furthermore this treat-
ment technique has also advantages compared to tomotherapy, e.g. the faster treatment
time and a lower integral dose. A reduction of the integral dose in tomotherapy would
be possible with a sharper dose gradient in the superior and inferior borders of the field.
This could be reached with a variable field width, as already proposed in the original work
about tomotherapy [29].
Another advantage of arc therapy is the possibility to use a conventional linac for dose
delivery and therefore other degrees of freedom are available, e.g. different angles for col-
limator, treatment couch and different beam energies.
Of course the results of these planning comparisons are largely influenced by the opti-
mization method used for AMCBT and the planning approach used for the other treat-
ment techniques. A more general approach to compare single arc therapy techniques with
state-of-the-art intensity-modulated techniques was pursuited in a paper titled ‘Single-Arc
IMRT?’ [8]. The differences between fixed gantry IMRT, single-arc IMRT and tomother-
apy are investigated for the archetypical IMRT example case [9]. For this example, the
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optimal solution is calculable analytically and can therefore serve as a benchmark so-
lution in comparison to the solutions achievable with the different delivery techniques.
Tomotherapy provides the best dose shaping capabilities and comes closest to the optimal
solution. The authors concluded that single-arc IMRT is an efficient dose delivery tech-
nique, but that for complex cases the quality of the dose distribution is not as good as
for tomotherapy. Even this analytical approach led to a discussions on the capabilities of
single arc therapy with variable dose rate, since the authors had to make assumptions on
the implementation of the dose delivery techniques, e.g. the collimator angle ([41], [69]).
Some considerations on a general theory for arc therapy with variable dose rate could be
found in [74].
Sensitivity of plan quality
The stability of the treatment plan quality was examined for the inclusion of hardware
constraints into the optimization algorithm, for different primary fluences, for the number
of beam directions used for treatment planning, for different collimator angles, for different
MLC leaf widths, for a restriction of the dose rate to constant values and for possible dose
delivery errors.
Optimization of treatment plans for AMCBT with a non flattened beam results in dose
distributions with good conformity to the tumor volume and sparing of adjacent OARs.
For the three cases under investigation the differences in target coverage, conformity and
OAR sparing were small. Disadvantages of removing the beam flattening filter are an
increase in the number of monitor units needed for treatment and an approximately 5%
increased mean dose inside the patient contour. Further research is necessary to analyse
the possible treatment time reduction for the higher dose rate achievable without a beam
flattening filter. Moreover, measurements need to be performed to verify the dose distri-
butions that were calculated for the non-flattened primary fluence.
Even though more beam directions lead to a higher number of DOF for the planning
process it was shown for the example of a prostate cancer patient that the quality of the
dose distribution was not improved with 72 beams compared to 36 beams. Also for other
example cases there was no improvement on the beam quality by increasing the number
of beams from 36 beams to 51 beams. The sampling rate seems to be high enough to
accurately model the dose distribution for the rotational dose delivery, at least an interpo-
lation of the small number of beams to 360 beam directions showed only a slight influence
on the dose distribution.
The choice of the collimator angle was shown to have an impact on the quality of the dose
distribution. For many of the example patient cases a collimator angle of 0◦ was best.
This is presumable based on the choice of the initial solution and might vary for other
optimization concepts.
The standard setting used for the size of the bixels was (5 mm)2. As assumed, it was
shown that wider MLC leaves result in an increased dose to the OARs.
A restriction of the dose rate to constant values results in a degradation of the plan quality
for most cases. If the DOF to vary the field weights is turned off in the optimization only
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the shape of the field could be varied to conform the dose to the target. If the restriction
of a constant dose rate is not considered in the optimization and the dose distribution
is recalculated for a constant dose rate with the field shapes that were optimized before,
there is an even larger degradation of the plan quality.
The analysis of the sensitivity of AMCBT treatment plans against dose delivery errors
showed a small influence of random MLC leaf displacements and bigger differences for
systematic displacements. Dose rate errors particularly influenced the dose distribution if
the dose rate was higher or lower as planned for the complete treatment. If the dose rate
was only altered for very high and low values the influence was less distinctive. The dose
distribution seems to be not very sensitive on an angular displacement of the gantry.
A more detailed analysis with the knowledge that was gained from the measurements
would intensify the knowledge on the sensitivity of AMCBT treatment plans against dose
delivery errors. For example the MLC measurements have shown small leaf displacements
in particular at inflecting points in the leaf trajectory profiles and the influence of this
on the dose distribution was not examined yet. For the gantry rotation only positioning
errors were investigated. If the speed is systematically lower or faster for the complete
treatment this would give the same results as a higher or lower dose rate. But how would
a variation of the gantry rotation speed during irradiation influence the dose distribution?
A recalculation of the dose distributions based on the information that was gained during
irradiation (e.g. the MLC log files and the information on the flat panel images) is also
an interesting project to further explore the influence of errors that might happen during
irradiation.
Dose delivery
In this thesis a hardware solution for the performance of arc-modulated cone beam ther-
apy was presented. First, AMCBT requires a linac with the ability to vary the dose rate
during irradiation. The solution used for this thesis project is a board that interrupts
the DRCV signaling pathway and multiplies the constant DRCV value with a modulation
function. It was shown that with this solution a fast and accurate variation of the dose
rate is possible. The second component needed for AMCBT is a dynamically controlled
MLC. Comparisons of planned and realized leaf positions demonstrated the ability of the
MLC to move the leaves in accordance with the planned positions. Information about
the realized leaf positions was gained from the MLC log files and from flat panel images
made during irradiation. Small deviations were visible at the inflection points of the leaf
trajectory profiles.
The verification of dose distributions calculated for AMCBT showed deviations that in
some cases exceeded the acceptance criteria. The absolute dosimetry with the ionization
chambers showed a very good agreement of the calculated and measured values in a num-
ber of measurements for a treatment plan that was optimized for a prostate cancer patient.
The results of the dose measurements were reproduced in a number of measurements very
accurately. These measurements verified the dose distribution that was calculated for
AMCT for a number of points in the dose distribution. However, the film measurements
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indicate that for low doses there were deviations exceeding the acceptance criteria.
For the C-shaped dose distribution that was delivered with a decreasing dose rate and
MLC leaves traveling back and forth there were deviations of up to almost 9% measured
for doses below 0.3 Gy. Again, the similarity between two measurements was very high,
e.g. for a calculated dose of 0.106 Gy doses of 0.114 Gy and 0.115 Gy were measured. So
the difference between calculated and measured dose for this example is 0.009 Gy, which
might be caused by leakage radiation and explain the deviation of 9%.
A more detailed and quantitative analysis of dosimetric verification measurements for AM-
CBT is needed, like for example reported for RapidArcTM [28], [35], [26], [5], [4]).
In this thesis project the feasibility to deliver dose distributions that were optimized for
AMCBT was shown and first experiments showed an acceptable agreement for dose values
exceeding approximately 0.3 Gy.
To conclude, dose delivery in a single arc is a promising dose delivery technique. The
newly developed optimization concept for AMCBT was used to demonstrate the ability
to deliver dose distributions with a quality similar to other intensity-modulated treat-
ment techniques in a single arc. For a variety of tumor types treatment plans of clinically
acceptable quality were presented in this thesis. The feasibility to deliver those dose dis-
tributions was proven with a newly developed hardware solution which uses a dynamic
MLC to shape the fields and an electronic board to vary the dose rate during irradiation.
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